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Provided herein are novel small-molecules that have use in 
the inhibition of Eis, which mediates kanamycin resistance 
in Mycobacterium tuberculosis. The presently-disclosed 
subject matter further includes a pharmaceutical composi-
tion including a small molecule inhibitor, as described 
herein, and a suitable pharmaceutical carrier. Methods of 
treating tuberculosis comprising administering to an indi-
vidual an effective amount of the disclosed small molecule 
inhibitors to mediate kanamycin A resistance and treat 
tuberculosis are also provided. 
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EIS INHIBITORS 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Application Ser. No. 62/268,244, filed Dec. 16, 2015, the 
entire disclosure of which is incorporated herein by this 
reference. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
National Institutes of Health (NIH) Grant AI090048. The 
govermnent has certain rights in the invention. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to compo-
sitions useful as inhibitors of acetyltransferase Eis, a media-
tor ofkanamycin resistance in Mycobacterium tuberculosis, 
and their methods of use. In particular, the compositions are 
sulfonamide-based and sulfonyl isothiazole-based small 
molecules. 
INTRODUCTION 
A major cause of tuberculosis (TB) resistance to the 
aminoglycoside kanamycin (KAN) is the Mycobacterium 
tuberculosis (Mtb) acetyltransferase Eis. Eis is a super-
acetyltransferase from M. tuberculosis that inactivates all 
clinically used aminoglycosides. Upregulation of Eis is a 
frequent cause of clinical resistance to the aminoglycoside 
kanamycin (KAN) in TB. Upregulation of this enzyme is 
responsible for inactivation of KAN through acetylation of 
its amino groups. 
Tuberculosis (TB) is an infectious disease caused by 
Mycobacterium tuberculosis (Mtb ), and a major global 
health threat. In 2013, approximately 9.0 million people 
developed TB, and nearly 1.5 million died from the disease. 
Due to the spread of multidrug-resistant TB (MDR TB), 
defined as TB with resistance to at least isoniazid and 
rifampin (-10% of new TB cases in 2013) and extensively 
drug-resistant TB (XDR TB), defined as MDR TB with 
added resistance to at least a fluoroquinolone and an inject-
able drug (i.e., kanamycin (KAN), capreomycin, or amika-
cin), the need for novel strategies to combat drug resistant 
TB is urgent. 
The aminoglycosides (AGs) kanamycin A (KAN) and 
amikacin (AMK) are used to treat MDR- and XDR-TB, but 
resistance to these agents occurs as well. Among mecha-
nisms of clinically important transmissible drug resistance is 
the recently identified inactivation of an MDR-TB therapeu-
tic, the aminoglycoside kanamycin, through its acetylation 
2 
Multiacetylation by Eis has a defined pattern for each AG: 
the number of acetylations and the positions of the amino 
groups that get acetylated depend on the structure of the AG. 
Furthermore, Eis homologues from Mycobacterium smeg-
matis, Mycobacterium abscessus, Anabaena variabilis, 
Bacillus anthracis, Gordonia bronchialis, Kocuria rhizo-
phila (9), and Tsukamurella paurometabola are also func-
tional AACs, which exhibit differences in regiospecificity 
and can be inhibited by chlorhexidine, a non-clinically 
10 relevant Eis_Mtb inhibitor. In addition to AG substrate 
versatility, Eis enzymes display some acyl-CoAco-substrate 
promiscuity and can acetylate non-AG molecules containing 
lysine residues, such as capreomycin and the JNK-specific 
dual-specificity protein phosphatase 16 (DUSP16)/mitogen-
15 activated protein kinase phosphatase-7 (MKP-7) pair. These 
observations underscore the uniqueness and versatility of 
Eis AG modifying activity and its high capacity for inacti-
vation of diverse AG drugs. 
The development of AGs that cannot be modified by Eis 
20 or a novel therapy that would involve an Eis inhibitor used 
in combination with KAN are two possible approaches to 
resolve the need in the field of drug resistant tuberculosis. 
The former route is complicated by the ability of Eis to 
accept structurally diverse AGs as substrates, whereas the 
25 latter route is potentially more suitable. The latter approach 
to combat drug resistance arising as a result of drug-
modifying enzymes, then, is to use a combination therapy 
that includes an antibiotic along with an inhibitor of its 
associated resistance enzyme. In Mtb, including MDR TB, 
30 the combination of the ~-lactamase inhibitor clavulanate and 
the ~-lactam meropenem was demonstrated to overcome 
resistance to ~-lactam antibiotics. With this strategy in mind, 
efforts have also been made towards identifying inhibitors of 
aminoglycoside acetyltransferases (AACs) present in non-
35 mycobacteria, with limited pre-clinical progress, but these 
are not applicable for the mechanistically and structurally 
distinct Mtb Eis acetyltransferase. For example, aminogly-
coside-acetyl coenzyme A bi-substrate inhibitors were found 
to potently inhibit AAC(6') enzymes in vitro, but were not 
40 effective in cell-based assays. Numerous cationic peptides 
that inhibit AAC(6') enzymes in vitro were identified, but 
these also displayed no antibacterial effects against resistant 
bacterial strains due to membrane permeability issues. 
Finally, the natural product aranorosin was found to be an 
45 inhibitor of the bi-functional AAC(6')-Ie/APH(2")-Ia 
enzyme, and its combination with the aminoglycoside 
arbekacin was shown to stop the growth of a methicillin-
resistant Staphylococcus aureus strain. 
We previously reported that some Eis inhibitors displayed 
50 AG-competitive and mixed modes of action, establishing a 
proof of principle for inhibition of Eis in vitro. 
A two-drug combination therapy where one drug targets 
an offending cell and the other targets a resistance mecha-
nism to the first drug is a time-tested, yet underexploited 
55 approach to combat or prevent drug resistance in an infec-
tious disease. Furthermore, there remains a need for 
approaches to combat drug resistant TB. 
by an up regulated acety ltransferase, the Eis ( enhanced intra-
cellular survival) enzyme. We previously demonstrated that 
the Mtb Eis protein (Eis_Mtb) is an acetyltransferase 
capable of multiacetylating a variety of AGs, including the 
TB therapeutics KAN and AMK, via a random sequential 
mechanism, thereby abolishing the antibiotic activity of 
these drugs. The ability of acetylating an AG molecule at 60 
multiple amine positions due to its unique structure distin-
guishes Eis from other AG acetyltransferases (AA Cs), 
which are known to be exquisitely regiospecific. A crystal 
structure of Eis_Mtb in complex with coenzyme A and 
tobramycin demonstrated how tobramycin could interact 65 
with the Eis active site in two binding modes for the 
observed diacetylation of the 6'- and 3"-amines of this AG. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
US 10,208,000 B2 
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summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 5 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this summary or not. To avoid 
excessive repetition, this summary does not list or suggest 
all possible combinations of such features. 
The presently-disclosed subject matter includes compo- 10 
sitions useful as inhibitors of acetyltransferase Eis, a media-
In some embodiments, the compounds are included in a 
pharmaceutical composition. In some embodiments, the 
pharmaceutical composition includes the compounds of the 
present invention and a suitable pharmaceutical carrier. In 
some embodiments, compositions and pharmaceutical com-
positions include the small molecule compounds set forth 
herein, such as for example, the compounds in Tables 18, 4 
and 5, a suitable pharmaceutical carrier, and an aminogly-
coside. In some embodiments, the aminoglycoside is 
kanamycin (KAN). 
Methods of using the Eis inhibitors are also disclosed. In 
tor ofkanamycin resistance in Mycobacterium tuberculosis, 
and their methods of use. In particular, the compositions are 
sulfonamide-based and sulfonyl isothiazole-based small 15 
molecules. In some embodiments, the inhibitors can effec-
tively overcome kanamycin resistance in strains of Mtb. 
some embodiments, methods of inhibiting Eis include 
administering an effective amount of a composition includ-
ing the compounds disclosed herein, including those set 
forth in Tables 18, 4, or 5 is disclosed. In some embodi-
ments, such methods include administration of a compound 
selected from compounds 29, 30, 32-35, 37-39, 41, 43, and 
46 in Table 18. 
In some embodiments, the compositions are a compound 
of the formula: 
0 
R....._ ..... J'CC~Xo 
N II I I a 
# N O 
H 
wherein R is selected from the group consisting of 
0 c,D ~() 
Br 
Q 6 
OMe 
OMe 
OM,D y0. 
OMe 
0) , and c6 . 
In some embodiments, the compounds is of the formula of 
any one of compounds 33-47, as set forth in Table 18 herein. 
20 In some embodiments, the compound is according to the 
formula: 
25 
30 
wherein the Rl and R2 groups are according to the structures 
identified in Table 5 as 3i, 6b, 7b, Sa, Se, Ile, 12e, 13a, 13e, 
13g, 13i, 14c, 15e, 15f, 17i, 33a, 35e, 35g, 35h, 35i, 36d, 
37b, 37d, 46a, 46b, 46c, 46h, 52i, 62i, 81 b, Sig, 87b, 89b, 
35 112b, 112i, 115i, 116i, 139b, 139e, and 139i. In some 
embodiments, Eis inhibition is effectuated by administration 
of the disclosed compounds. 
In one aspect, the administration of the disclosed com-
pound yields a Minimal Inhibitory ConcentrationKanamycin 
40 (MICKANJ value is less than about 2.5 µg/mL to about 5 
µg/mL to a Mtb strain. In some embodiments, the MIC level 
is reduced to a level close to a KAN-susceptible Mtb strain, 
and can be characterized as fully overcoming kanamycin 
resistance. In some embodiments, the IC50 , that is, the 
45 concentration of an inhibitor's Eis inhibitory activity is 
increased. In some embodiments, the IC50 is about 0.08 µM 
to about 0.25 µM against purified Eis enzyme, in other 
embodiments, the IC50 is less than about 0.25 µM. 
Methods of administration can include, in some embodi-
50 ments, administering an aminoglycoside or a combination of 
drugs including an aminoglycoside. In some embodiments, 
the aminoglycoside is kanamycin (KAN). 
Methods of treating aminoglycoside-resistant Mycobac-
terium tuberculosis are also disclosed and include adminis-
55 tering the compounds of the present invention, including 
compounds as set forth in Tables 18, 4 and 5. In some 
embodiments, such methods of treatment include adminis-
tering an aminoglycoside, before, during or after treatment 
with the compounds of the present invention. In some 
60 embodiments, the aminoglycoside is administered with a 
combination of other active drugs. In some instances, the 
aminoglycoside is kanamycin (KAN). In one aspect, the 
methods of treatment include administering the aminogly-
coside and presently-disclosed compounds to a subject in 
65 need of treatment for aminoglycoside-resistant Mtb. 
A kit including the compounds as disclosed herein, for 
example, a compound as set forth in Tables 18, 4 and 5, 
US 10,208,000 B2 
5 
packaged together with an aminoglycoside are also dis-
closed. In some embodiments, the kit contains the amino-
glycoside kanamycin. 
6 
present invention(s). Each example is provided by way of 
explanation of the present disclosure and is not a limitation 
thereon. In fact, it will be apparent to those skilled in the art 
that various modifications and variations can be made to the 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features of the subject matter of the present 
disclosure are set forth with particularity in the following 
description and in the appended sample claims. A better 
understanding of the features and advantages of the pres-
ently disclosed subject matter will be obtained by reference 
to the following detailed description that sets forth illustra-
tive embodiments, in which the principles of the 
invention(s) are used, and the accompanying drawings. 
5 teachings of the present disclosure without departing from 
the scope of the disclosure. For instance, features illustrated 
or described as part of one embodiment can be used with 
another embodiment to yield a still further embodiment. 
All references to singular characteristics or limitations of 
10 the present disclosure shall include the corresponding plural 
characteristic(s) or limitation(s) and vice versa, unless oth-
erwise specified or clearly implied to the contrary by the 
context in which the reference is made. 
FIG. 1 shows representative dose response curves for 15 
sulfonamide inhibitors of the present invention with pure 
Eis. 
FIG. 2 is a cartoon view of the crystal structure of Eis in 
complex with compound 39 and CoA. FIG. 2a. provides the 
overall view of a monomer of Eis-CoA-inhibitor 39 com- 20 
plex; FIG. 2b. provides the zoomed-in view of the AG-
binding site with the bound inhibitor. The omit F 0 -F c map 
( contoured at 3a) generated without the inhibitor is shown as 
mesh. The bound CoA is omitted to avoid obstructing the 
view. The inhibitor is shown as sticks and the interacting 25 
side chains of Eis are shown as pale sticks. 
FIG. 3 is a schematic representation of the winnowing of 
-123,000 small organic molecules to 18 showing inhibition 
of both Eis enzymatic activity and growth of Mtb K204 in 
the presence of KAN. 
FIG. 4 provides crystal structures of EisC204A from Mtb 
in complex with 13g ( a and b) and l le ( c and d). The overall 
views of the Eis monomer with the inhibitors bound (a and 
30 
c) and zoom-in views of the active site (band d) show that 
the inhibitors occupy a site overlapping with the AG sub- 35 
strate-binding site. The F 0 -F c omit map contoured at 3a is 
shown by the mesh. Inhibitor interacting residues are shown 
as sticks. Water molecules mediating inhibitor binding are 
shown as navy blue spheres. The side chain of Asp26 and the 
backbone of this residue and its neighbors adopt different 40 
conformations in the two complexes. The CoAmolecule was 
observed in the same position as in previously reported 
structures, with the phosphopantetheinyl arm exhibiting 
disorder and is not shown for the sake of clarity. 
FIG. 5 includes representative IC50 plots for the inhibition 45 
of Eis using fresh powder for several of the inhibitors 
identified in Table 5. 
All combinations of method or process steps as used 
herein can be performed in any order, unless otherwise 
specified or clearly implied to the contrary by the context in 
which the referenced combination is made. 
The presently-disclosed subject matter includes com-
pounds that are useful for inhibiting Eis. In some embodi-
ments, the compound has the following structure: 
0 
R, /~U~XO N II I I a 
# N O H , 
where R is defined as set forth in Table 18, hereinbelow. In 
some embodiments, the compound is any one of compounds 
33-47, as set forth in Table 18. In some embodiments, the 
compound has the following structure: 
where R1 and R2 are defined as set forth in Tables 4 and 5. 
The presently-disclosed subject matter also includes com-
positions comprising one or more of compounds as set forth 
in Table 18. In some embodiments, the composition 
includes one or more of compounds 33-47, as set forth in DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
50 Table 18. In some embodiments, the composition includes 
one or more compounds as set forth in Tables 18, 4, and 5. 
In some embodiments, the composition includes one or 
more compounds identified in Table 5 as 3i, 6b, 7b, Sa, Se, 
The presently-disclosed subject matter is illustrated by 
specific but non-limiting examples throughout this descrip-
tion. The examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
55 
Ile, 12e, 13a, 13e, 13g, 13i, 14c, 15e, 15f, 17i, 33a, 35e, 
35g, 35h, 35i, 36d, 37b, 37d, 46a, 46b, 46c, 46h, 52i, 62i, 
Sib, Sig, 87b, 89b, 112b, 112i, 115i, 116i, 139b, 139e, and 
139i. In some embodiments, the composition is a pharma-
ceutical composition further comprising a pharmaceutically-
60 acceptable carrier. 
The presently-disclosed subject matter further includes 
methods or inhibiting Eis and methods of treating amino-
glycoside-resistant Mtb. In some embodiments the method 
involves administering a compound or composition as dis-
65 closed herein. In some embodiments, the method involves 
administering a compound or composition to a subject in 
need of treatment for aminoglycoside-resistant Mtb. In some 
US 10,208,000 B2 
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embodiments, the method further includes administering an 
aminoglycoside. In some embodiments the aminoglycoside 
is kanamycin (KAN). 
The terms "treat," "treatment," and the like refer to the 
medical management of a subject with the intent to cure, 
ameliorate, stabilize, or prevent a disease, pathological con-
dition, or disorder. This term includes active treatment, that 
is, treatment directed specifically toward the improvement 
of a disease, pathological condition, or disorder, and also 
includes causal treatment, that is, treatment directed toward 
removal of the cause of the associated disease, pathological 
condition, or disorder. In addition, this term includes pal-
liative treatment, that is, treatment designed for the relief of 
symptoms rather than the curing of the disease, pathological 
condition, or disorder; preventative (prophylatic) treatment, 
that is, treatment directed to minimizing or partially or 
completely inhibiting the development of the associated 
disease, pathological condition, or disorder; and supportive 
treatment, that is, treatment employed to supplement another 
specific therapy directed toward the improvement of the 
associated disease, pathological condition, or disorder. 
In some embodiments, a method is provided for treating 
antibiotic resistance and/or inhibiting Eis enzymatic activity 
in a cell. In some embodiment the method includes contact-
ing the cell with compounds disclosed herein. The term 
"contacting" as used herein refers to any means by which the 
compound is brought into sufficient proximity and/or in 
direct contact with a cell such that the cell is capable of 
receiving the compound. For instance, in some embodiments 
contact refers to coating or otherwise exposing a cell to the 
compound. In some embodiments contact refers to culturing 
a cell in a solution that includes the compound. In other 
embodiments the cell is within a subject, and contact refers 
to administering a compound to the subject such that a cell 
within the subject is capable of receiving the novel small 
molecule compounds. In some embodiments, such methods 
can include further administration of an antibiotic at the 
same time as the administration of the compound, or prior to 
or subsequent to the administration of compound. In some 
embodiments, the antibiotic is kanamycin. The presently-
disclosed subject matter further includes composition that 
include at least one compound disclosed herein as an Eis 
inhibitor, and an aminoglycoside. In some embodiments the 
aminoglycoside is kanamycin (KAN). In some embodi-
ments, the cell exhibits resistance to kanamycin. In some 
embodiments, said cell is within a subject diagnosed with 
tuberculosis. 
The presently-disclosed subject matter further includes 
kits comprising at least one compound disclosed herein as an 
Eis inhibitor, packaged together with an aminoglycoside. In 
some embodiments the aminoglycoside is kanamycin 
(KAN). 
The presently disclosed subject matter includes identified 
potent inhibitors of Eis enzymatic activity with resulting 
sensitization of KAN-resistant Mtb cells, in which the 
resistance to KAN is caused by Eis upregulation. The 
inhibitors bind in the AG binding pocket blocking the access 
of AGs to the active site of the enzyme. The inhibitor 
binding is accompanied by induced-fit conformational 
changes of the protein. These compounds have a great 
potential for further development as KAN adjuvants in Mtb. 
The presently-disclosed subject matter includes novel 
small molecule compositions, and small molecule compo-
sitions useful as inhibitors of Eis enzymatic activity. In some 
instances, the small molecule is a sulfonamide-based struc-
ture. In some embodiments, the small molecule is a sulfonyl 
8 
isothiazole-based composition. In some embodiments, the 
inhibitors can effectively overcome kanamycin resistance in 
strains of Mtb. 
In one aspect, the administration of the disclosed com-
pound yields a Minimal Inhibitory ConcentrationKanamycin 
(MICKANJ value is less than about 2.5 µg/mL for Mtb strains. 
In some embodiments, the MIC KAN is less than about 0.625 
µg/mL for Mycobacterium tuberculosis (Mtb) strain H37Rv, 
or less than about 5 µg/mL for Mtb strain K204. In some 
10 embodiments, the MIC level is reduced to a level close to a 
KAN-susceptible Mtb strain, and can be characterized as 
fully overcoming kanamycin resistance. For example, in 
Mtb strain K204, a measured MIC KAN of less than or equal 
to 1.25 µg/mL would indicate a compound with inhibitory 
15 activity sufficient to overcome kanamycin resistance. As 
such, in some embodiments, the KAN MIC values of a 
compound are expressed as a 2-fold, four fold, 8-fold or 
more reduction in KAN MIC against a Mtb strain. 
In some embodiments, the IC50 , the concentration of an 
20 inhibitor's Eis inhibitory activity is measured. In some 
embodiments, the IC50 is about 0.08 µM to about 0.25 µM 
against purified Eis enzyme. However, as one skilled in the 
art will recognize, compounds can reduce the MIC value of 
a KAN-resistant Mtb strain with IC50 values that vary 
25 according to how measured. For example, in vitro measure-
ments differ from those values measured in cellulo or in 
vivo. For example, IC50 values ranging from 0.1 to about 
4.35 µM when measured in cellulo or in vivo can be 
indicative of an effective Eis inhibitor, as these activities are 
30 not exactly correlated. Such variances can be for a wide 
variety of reasons, including, for example, based upon 
difficulty of small molecules penetrating the waxy cell wall 
of Mycobacteria. 
Methods of treating kanamycin resistance are also dis-
35 closed herein, comprising administering a small molecule 
composition disclosed herein. Also provided are methods of 
treating tuberculosis comprising administering the Eis 
inhibitors disclosed herein with kanamycin. The presently-
disclosed subject matter further includes a pharmaceutical 
40 composition including a small molecule, as described 
herein, and a suitable pharmaceutical carrier. The presently-
disclosed subject matter also includes a method of treating 
a bacterial infection comprising administering to an indi-
vidual an effective amount of a small molecule Eis inhibitor, 
45 as disclosed herein. In some instances, the pharmaceutical 
composition is administered with an aminoglycoside. In 
some instances the aminoglycoside is Kanamycin. 
While the following terms used herein are believed to be 
well understood by one of ordinary skill in the art, defini-
50 tions are set forth to facilitate explanation of the presently-
disclosed subject matter. 
The terms "polypeptide", "protein", and "peptide", which 
are used interchangeably herein, refer to a polymer of the 
protein amino acids, or amino acid analogs, regardless of its 
55 size or function. Although "protein" is often used in refer-
ence to relatively large polypeptides, and "peptide" is often 
used in reference to small polypeptides, usage of these terms 
in the art overlaps and varies. The term "polypeptide" as 
used herein refers to peptides, polypeptides, and proteins, 
60 unless otherwise noted. The terms "protein", "polypeptide", 
and "peptide" are used interchangeably herein when refer-
ring to a gene product. Thus, exemplary polypeptides 
include gene products, naturally occurring proteins, 
homologs, orthologs, paralogs, fragments and other equiva-
65 lents, variants, and analogs of the foregoing. 
Unless otherwise indicated, the term "administering" is 
inclusive of all means known to those of ordinary skill in the 
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In some embodiments the subject in need thereof will be 
suffering or will have been diagnosed tuberculosis and/or 
related diseases, disorders, pathologies, or conditions. 
As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel-
opment of a condition of interest; inhibiting the progression 
art for providing a preparation to a subject, including admin-
istration by inhalation, nasal administration, topical admin-
istration, intravaginal administration, ophthalmic adminis-
tration, intraaural administration, intracerebral 
administration, intravitreous administration, intracameral 
administration, posterior sub-Tenon administration, poste-
rior juxtascleral administration, subretinal administration, 
suprachoroidal administration, cell-based administration or 
production, rectal administration, and parenteral administra-
tion, including injectable such as intravenous administra-
tion, intra-arterial administration, intramuscular administra-
tion, and/or subcutaneous administration. Administration 
can be continuous or intermittent. A preparation can be 
administered therapeutically; that is, administered to treat an 
existing condition of interest. A preparation can be admin-
istered prophylactically; that is, administered for prevention 
of a condition of interest. 
10 of a condition of interest; arresting or preventing the devel-
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
associated with a condition of interest; and causing a regres-
sion of the condition of interest or one or more of the 
15 symptoms associated with the condition of interest. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any In some embodiments a subject will be administered an 
effective amount of at least one compound and/or compo-
sition provided in the present disclosure. In this respect, the 
term "effective amount" refers to an amount that is sufficient 
to achieve the desired result or to have an effect on an 
20 methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
undesired condition. For example, a "therapeutically effec-
tive amount" refers to an amount that is sufficient to achieve 25 
the desired therapeutic result or to have an effect on unde-
sired symptoms, but is generally insufficient to cause 
adverse side effects. The specific therapeutically effective 
dose level for any particular patient will depend upon a 
variety of factors including the disorder being treated and 30 
the severity of the disorder; the specific composition 
employed; the age, body weight, general health, sex and diet 
of the patient; the time of administration; the route of 
administration; the rate of excretion of the specific com- 35 
pound employed; the duration of the treatment; drugs used 
in combination or coincidental with the specific compound 
employed and like factors well known in the medical arts. 
For example, it is well within the skill of the art to start doses 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "an enzyme" includes a plurality of such enzymes, 
and so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±50%, in some embodiments 
±40%, in some embodiments ±30%, in some embodiments 
±20%, in some embodiments ±10%, in some embodiments 
±5%, in some embodiments ±1 %, in some embodiments 
±0.5%, and in some embodiments ±0.1 % from the specified 
amount, as such variations are appropriate to perform the 
disclosed method. 
of a compound at levels lower than those required to achieve 40 
the desired therapeutic effect and to gradually increase the 
dosage until the desired effect is achieved. If desired, the 
effective daily dose can be divided into multiple doses for 
purposes of administration. Consequently, single dose com-
positions can contain such amounts or submultiples thereof 45 
to make up the daily dose. The dosage can be adjusted by the 
individual physician in the event of any contraindications. 
Dosage can vary, and can be administered in one or more 
dose administrations daily, for one or several days. Guidance 
can be found in the literature for appropriate dosages for 
given classes of pharmaceutical products. In further various 
aspects, a preparation can be administered in a "prophylac-
tically effective amount"; that is, an amount effective for 
prevention of a disease or condition. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
50 value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
Additionally, the terms "subject" or "subject in need 
thereof' refer to a target of administration, which optionally 
displays symptoms related to a particular disease, pathologi-
55 two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
cal condition, disorder, or the like. The subject of the herein 
disclosed methods can be a vertebrate, such as a mammal, a 
fish, a bird, a reptile, or an amphibian. Thus, the subject of 60 
the herein disclosed methods can be a human, non-human 
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea 
pig or rodent. The term does not denote a particular age or 
sex. Thus, adult and newborn subjects, as well as fetuses, 
whether male or female, are intended to be covered. A 65 
patient refers to a subject afflicted with a disease or disorder. 
The term "subject" includes human and veterinary subjects. 
As will be recognized by one of ordinary skill in the art, 
the terms "reduce", "reducer", "reduction", "reducing", 
"suppression," "suppressing," "suppressor," "inhibition," 
"inhibiting" or "inhibitor" do not refer to a complete elimi-
nation of angiogenesis in all cases. Rather, the skilled artisan 
will understand that the term "reducing", "suppressing" or 
"inhibiting" refers to a reduction or decrease in a particular 
condition. Such reduction or decrease can be determined 
relative to a control. In some embodiments, the reduction or 
decrease relative to a control can be about a 1, 2, 3, 4, 5, 6, 
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7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 
24,25, 26,27,28, 29, 30,31,32, 33,34,35,36, 37,38,39, 
40,41, 42,43,44, 45, 46,47,48, 49, 50, 51, 52, 53, 54, 55, 
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 
88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% 
decrease. 
As described herein, the presently-disclosed subject mat-
ter further includes pharmaceutical compositions compris-
ing at least one enzyme described herein together with a 10 
pharmaceutically acceptable carrier. 
The term "pharmaceutically acceptable carrier" refers to 
sterile aqueous or nonaqueous solutions, dispersions, sus-
pensions or emulsions, as well as sterile powders for recon-
stitution into sterile injectable solutions or dispersions just 15 
prior to use. Proper fluidity can be maintained, for example, 
by the use of coating materials such as lecithin, by the 
maintenance of the required particle size in the case of 
dispersions and by the use of surfactants. These composi-
tions can also contain adjuvants such as preservatives, 20 
wetting agents, emulsifying agents and dispersing agents. 
Prevention of the action of microorganisms can be ensured 
by the inclusion of various antibacterial and antifungal 
agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic 25 
agents such as sugars, sodium chloride and the like. Pro-
longed absorption of the injectable pharmaceutical form can 
12 
calcium hydrogen phosphate); lubricants (e.g., magnesium 
stearate, talc or silica); disintegrants (e.g., potato starch or 
sodium starch glycolate); or wetting agents (e.g., sodium 
lauryl sulphate). The tablets can be coated by methods 
known in the art. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 
with pharmaceutically acceptable additives such as suspend-
ing agents ( e.g., sorbitol syrup, cellulose derivatives or 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 
preservatives ( e.g., methyl or propyl-p-hydroxybenzoates or 
sorbic acid). The preparations can also contain buffer salts, 
flavoring, coloring and sweetening agents as appropriate. 
Preparations for oral administration can be suitably formu-
lated to give controlled release of the active compound. For 
buccal administration the compositions can take the form of 
tablets or lozenges formulated in conventional manner. 
The compositions can be formulated as eye drops. For 
example, the pharmaceutically acceptable carrier may com-
prise saline solution or other substances used to formulate 
eye drop, optionally with other agents. Thus, eye drop 
formulations permit for topical administration directly to the 
eye of a subject. 
The compositions can also be formulated as a preparation 
be brought about by the inclusion of agents, such as alumi-
num monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as 
polylactide-polyglycolide, poly(orthoesters) and poly(anhy-
drides ). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro-
emulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo-
rating sterilizing agents in the form of sterile solid compo-
sitions which can be dissolved or dispersed in sterile water 
or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
30 for implantation or injection. Thus, for example, the com-
pounds can be formulated with suitable polymeric or hydro-
phobic materials (e.g., as an emulsion in an acceptable oil) 
or ion exchange resins, or as sparingly soluble derivatives 
(e.g., as a sparingly soluble salt). The compounds can also 
35 be formulated in rectal compositions, creams or lotions, or 
transdermal patches. 
The presently-disclosed subject matter further includes a 
kit that can include an enzyme and/or a pharmaceutical 
composition as described herein, packaged together with a 
40 device useful for administration of the compound or com-
position. As will be recognized by those or ordinary skill in 
the art, the appropriate administration-aiding device will 
depend on the formulation of the compound or composition 
that is selected and/or the desired administration site. For Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 45 
buffers, bacteriostats, bactericidal antibiotics and solutes 
that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 
suspensions, which can include suspending agents and 
thickening agents. 50 
The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable 55 
vehicle, e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) 
condition requiring only the addition of sterile liquid carrier 60 
immediately prior to use. 
For oral administration, the compositions can take the 
form of, for example, tablets or capsules prepared by a 
conventional technique with pharmaceutically acceptable 
excipients such as binding agents ( e.g., pregelatinized maize 65 
starch, polyvinylpyrrolidone or hydroxypropyl methylcellu-
lose ); fillers ( e.g., lactose, microcrystalline cellulose or 
example, if the formulation of the compound or composition 
is appropriate for injection in a subject, the device could be 
a syringe. For another example, if the desired administration 
site is cell culture media, the device could be a sterile 
pipette. 
The presently-disclosed subject matter includes novel 
small molecules. Also disclosed are small molecules that 
inhibit Eis. Small molecule Eis inhibitors disclosed herein 
aid in reducing KAN resistance and/or restoring KAN 
susceptibility in Mycobacterium tuberculosis. The pres-
ently-disclosed subject matter further includes a pharmaceu-
tical composition including a small molecule inhibitor, as 
described herein, and a suitable pharmaceutical carrier, 
optionally administered with Kanamycin. The presently-
disclosed subject matter further includes a method of treat-
ing tuberculosis, including aminoglycoside resistant tuber-
culosis, comprising administering to an individual an 
effective amount of a small molecule Eis inhibitor, as 
disclosed herein, to inhibit the Eis acetyltransferase of 
Mycobacterium tuberculosis and reduce KAN resistance 
and/or restore KAN susceptibility. 
In certain embodiments, the present disclosure further 
provides a method of treating, preventing and/or reducing 
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kanamycin resistance and/or restoring KAN susceptibility in 
Mycobacterium tuberculosis. The method comprises at least 
the step of administering an effective amount of a small 
molecule inhibitor provided in the present disclosure to a 
subject. In some embodiments, the subject is in need of 
treatment. In some instances, the Mycobacterium tubercu-
losis strain is Mtb K204 or H137Rv. In some embodiments, 
the small molecule is administered with an aminoglycoside, 
for example, kanamycin. In some embodiments, the treat-
ment reduces and/or eliminates the Eis-mediated KAN resis- 10 
tance of Mycobacterium tuberculosis. 
14 
These Eis inhibitors are useful for the pre-clinical develop-
ment of innovative AG combination therapies against resis-
tant TB. 
Identification and Chemical Synthesis of Eis Inhibitors. 
To identify potential Eis inhibitor candidates, over 123, 
000 structurally diverse small molecules were screened by 
an established UV absorbance-based HTS assay (12) for 
their inhibition of KAN acetylation by the Eis_Mtb acetyl-
transferase in vitro. The screening of this molecular library 
against Eis_Mtb led to the identification of a sulfonamide 
scaffold (Table 18). The HTS library contained 29 com-
pounds (1-29) with this core structure, and four of them (1-3 
and 29) were identified as hits (i.e., compounds 
displaying ;;,;3-fold inhibition than the standard deviation 
Additionally, in certain embodiments, the inhibitors of the 
present disclosure have a Mtb strain K204 Minimal Inhibi-
tory ConcentrationKanamycin (MICKAN) value of less than 
about 5.0 µg/mL, of less than about 2.5 µg/mL, or less than 
about 1.25 µg/mL. In other embodiments, the inhibitors have 
a MIC KAN value of less than about 0.625 µg/mL for Myco-
bacterium tuberculosis (Mtb) strain H37Rv. 
The presently-disclosed subject matter is illustrated by the 
following specific but non-limiting examples. The following 
examples may include compilations of data that are repre-
sentative of data gathered at various times during the course 
of development and experimentation related to the present 
invention. 
15 ( calculated for the inert compounds at 20 µM)). Compounds 
4-28 were found not to inhibit Eis in the HTS. However, 
compounds 1-3 displayed some Eis inhibition and com-
pound 29 potently inhibited Eis activity (IC50=0.5±0.1 µM). 
Based on this encouraging result, compound 29 along with 
20 18 additional sulfonamide analogues (30-47) containing a 
variety of substituents on the aniline ring to define a pre-
liminary body of structure-activity relationship (SAR) of Eis 
inhibition were freshly synthesized. The compounds evalu-
ated in this work were synthesized according to the synthetic 
EXAMPLES 
25 pathway described in Table IA. In the first step, which is 
common to all compounds, 2,3-dihydroxyquinoxaline was 
reacted with chlorosulfonic acid and the resulting sulfonyl 
chloride was then reacted with different aniline derivatives 
to obtain compounds 29-47. The discovery and rational structure-based optimization 
via medicinal chemistry of promising Eis inhibitors that not 30 
only efficiently inhibit the purified enzyme, but also restore 
KAN susceptibility of KAN-resistant Mtb are reported 
herein. Also reported is a crystal structure of Eis in complex 
with CoA and one potent sulfonamide inhibitor, which 
35 
reveals its mode of action, explaining the SAR study and 
provides for further rational structure-based development of 
Eis inhibitors. 
The inventors of the present invention set out to identify 
inhibitors of Eis that could be co-administered with KAN in 40 
order to prevent inactivation by Eis in Mtb. Herein the 
identification as well as the biochemical and biological 
characterization of several potent inhibitors of Eis are 
reported that were able to restore the antibacterial activity of 
KAN in a KAN-resistant strain, Mtb K204. To clarify in 45 
atomic details the mode of action of these compounds and 
their structure-activity-relationships, crystal structures of 
EisC204A in complex with CoA and two of these inhibitors 
were also determined. 
50 
Example 1 
By high-throughput screening, a sulfonamide scaffold 
was identified that was used as a pharmacophore to generate 
inhibitors of the Mycobacterium tuberculosis acetyltrans- 55 
ferase Eis, whose upregulation causes resistance of tuber-
culosis (TB) to the aminoglycoside (AG) antibiotic kanamy-
cin A (KAN). Rational systematic derivatization of this 
scaffold to maximize Eis inhibition in the test tube as well 
as to abolish the Eis-mediated KAN resistance of Mycobac- 60 
terium tuberculosis in vivo yielded several highly potent 
agents. A crystal structure of Eis in complex with one of the 
most potent inhibitors revealed that it bound Eis in the 
AG-binding pocket interacting with a conformationally mal-
leable region of Eis (residues 28-37) bearing key hydropho- 65 
bic residues. This adaptable region apparently accommo-
dates different inhibitor functionalities that interact with it. 
TABLE 1 
A. Synthetic scheme used for the preparation of the molecules generated 
in this study. B. Structures of molecules used in this study. 
CC~xo N O 
H 
l:R~ 
2:R~ 
0 
X~H,Me 
4-100% 
Ar'-. ... JU~XO 
N II I I o 
X # N O 
H 
29-47 
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TABLE I-continued 
A. Synthetic scheme used for th . in this study. B. Structur e p~eparat10n of the molecules generated 
es o molecules used in this study. 
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TABLE I-continued 
A. Synthetic scheme used fo th . in this study. B. Struc~re: ~;parto: of the molecules generated 
mo ecu es used in this study. 
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TABLE 1 . 
A Synthet' -contmued 
in l~ scheme used for this study. B. Struc!e preparation of the es of m 
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TABLE I-continued 
A. Synthetic scheme used for the preparation of the molecules generated 
in this study. B. Structures of molecules used in this study. 
46: R~ 
OMe 
47:R~ 
~-ca 
10 
15 
20 
20 
TABLE 2-continued 
IC50 values against purified Eis and MIC values against Mtb 
H37Rv and Mtb K204. 
Compound# ICso (µM)" 
32 10.6 ± 2.5 
33 5.8 ± 1.8 
34 0.100 ± 0.045 
35 0.25 ± 0.06 
36 >200 
37 3.0 ± 0.7 
38 0.056 ± 0.004 
39 5.8 ± 1.2 
40 7.4 ± 3.3 
41 0.37 ± 0.09 
42 0.027 ± 0.012 
43 0.23 ± 0.03 
44 0.7 ± 0.3 
45 27 ± 8 
46 0.00024 ± 0.00010 
47 0.30 ± 0.08 
aIC50 values against purified Eis enzyme, 
banti-TB activity of KAN against Mtb H37Rv, 
canti-TB activity of KAN against Mtb K204. 
H37Rv MIC KAN K204 MIC KAN 
(µg/mLl (µg/mL)" 
,;1.25 
,;1.25 
,;1.25 2.5 
,;1.25 2.5-5 
,;1.25 10 
,;1.25 
,;1.25 2.5 
,;1.25 ,;1.25 
,;1.25 5-10 
,;1.25 2.5-5 
,;1.25 5-10 
,;1.25 2.5-5 
,;1.25 5-10 
,;1.25 5-10 
,;1.25 ,;1.25 
,;1.25 10 
Having established the importance of the N-methyl moi-
Biochemical and Biological Testing of Sulfonamides 
29-47. 
To investigate the potential of these compounds as Eis 
inhibitors for use in combination with KAN, their biochemi-
25 ety, the effect of substitutions on the benzene ring of the 
aniline moiety were explored. Removing all substituents on 
the benzene ring (compound 33) resulted in a 70-fold 
decrease in Eis inhibitory activity (IC50=5.8±1.8 µM) when 
30 compared to that of lead 29 and did not overcome KAN 
resistance in Mtb K204, suggesting the importance of a 
substituted aniline for Eis inhibition and antitubercular 
activity. In general, para substitution ( compounds 29 with a 
cal (IC50 values against purified Eis enzyme) and biological 
(effect on the MIC values of KAN in KAN-sensitive Mtb 
H37Rv and in Mtb K204, which is KAN-resistant due to Eis 
upregulation properties were evaluated in parallel studies 
(Table 2 and FIG. 1). The freshly synthesized compound 29 
displayed robust inhibition of Eis in vitro (IC50=0.08±0.02 35 
µM). When combined with KAN, sulfonamide 29, resulted 
in a four-fold reduced KAN MIC value (2.5 µg/mL) com-
pared to KAN alone (10 µg/mL) for K204 Mtb. This was a 
reduction almost to the MIC level of KAN in the KAN-
susceptible Mtb H37Rv (1.25 µg/mL) parent strain. To gain 
insight into the importance of the substitution pattern on the 40 
aniline portion of the sulfonamide scaffold, secondary 
(NHAr) and tertiary (N(Me)Ar) sulfonamides (29-47) were 
first generated. Eis inhibition assays with the synthesized 
sulfonamides were carried out in combination with KAN. 
The non-methylated counterpart oflead compound 29, com- 45 
pound 30, displayed lower Eis inhibitory activity 
(IC50=6.24±1.31 µM) and, contrary to 29, did not overcome 
KAN resistance in Mtb K204 (MICKAN=lO µg/mL). Two 
other non-methylated derivatives, 31 and 32, also resulted in 
lower Eis inhibitory activity (IC50>200 and 10.6±2.5 µM, 50 
respectively) and did not overcome KAN resistance in Mtb 
K204 (MICKAN=lO and 5 µg/mL, respectively). These data, 
p-Br, 34 with a p-Cl, and 35 with a p-iPr) was found to be 
highly favorable and yielded compounds with IC50 values 
varying from 0.08-0.25 µM, which overcame KAN resis-
tance (MICKAN=2.5 µg/mL) in KAN-resistant Mtb. Interest-
ingly, p-methoxy substitution resulted in a compound (13) 
that was found to be inactive during our HTS. To delineate 
if ortho or meta substitution would be even more favorable 
than para substitution, we generated compounds 36 (with an 
o-OMe) and 39 (with a m-OMe ). The o-methoxy substituted 
36 was found to be completely inactive (IC50>200 µM and 
MICKAN=lO µg/mL against Mtb K204), whereas the 
m-methoxy substituted 39 was found to be a potent Eis 
inhibitor (IC50=5.8±1.2 µM) and was one of our two com-
pounds to fully overcome KAN resistance in Mtb K204 
(MICKANsl .25 µg/mL). It is important to note that incorpo-
rating an additional m-methoxy group, as in compound 40, 
was detrimental for the overall activity of the molecule, 
which suggested that mono-substitution is more promising 
than di-substitution. We also synthesized the m-bromo 
derivative 38, which demonstrated a slightly improved Eis 
inhibitory activity (IC50=0.056±0.004 µM) than did the 
in conjunction with the fact that compounds 1-12 from the 
HTS did not display significant Eis inhibition, suggest that 
the N-methyl group is essential for efficient Eis inhibition 
and antitubercular activity. 
TABLE 2 
IC50 values against purified Eis and MIC values against Mtb 
H37Rv and Mtb K204. 
55 corresponding para derivative 29, while also being able to 
overcome KAN resistance in Mtb K204 (MIC=2.5 µg/mL). 
We also found that the m-iso-propyl derivative 43 and its 
para counterpart 35 displayed similar Eis inhibitory activity 
(IC50=0.23±0.03 and 0.25±0.06 µM, respectively) and 
Compound# ICso (µM)" 
29 0.08 ± 0.02 
30 6.2 ± 1.3 
31 >200 
H37Rv MICKAN 
(µg/mLl 
1.25 
,;1.25 
,;1.25 
,;1.25 
K204 MICKAN 
(µg/mL)" 
10 
2.5 
10 
60 resulted in identical KAN MIC values (2.5-5n/mL) against 
KAN-resistant Mtb. While the p-methyl derivative 14 was 
inactive in our HTS, its meta counterpart 41 displayed good 
Eis inhibition (IC50=0.37±0.09 µM) and some ability to 
overcome KAN resistance in Mtb K204 (MIC 2.5-5 µg/mL). 
These data suggest that mono-mew substitution is either 
equal or more advantageous then para, which is more 
beneficial than ortho. Based on these results, we generated 
65 
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additional m-alkylated sulfonamides (42, 44, and 45) and 
observed that longer or bulkier alkyl groups, although good 
for Eis inhibition, did not produce compounds capable of 
overcoming KAN resistance in Mtb K204. Finally, with the 
hope of increasing any possible Jt-Jt interaction between the 
inhibitor and the AG-binding site of the Mtb Eis, we 
generated compound 46, which showed an incredible 
increase in Eis inhibitory activity (IC50=0.00024±0.00010 
µM) and was found to completely overcome KAN resistance 
in Mtb K204 (MICKANsl.25 µg/mL). Compound 46 is 
currently our most potent and promising Eis inhibitor that 
can be used in conjunction with KAN. 
To examine the selectivity of our two best inhibitors (39 
and 46) towards Eis, next these two compounds were tested 
against three other AAC enzymes: AAC(2')-Ic from Mtb 
(17, 18), AAC(3)-IV from E. coli (19, 20), and AAC(6')-Ie/ 
APH(2")-Ia from Staphylococcus aureus (21, 22). Sulfona-
mides 39 and 46 did not inhibit KAN acetylation by the 
AACs tested at concentrations as high as 200 µM with the 
exception of 39, which inhibited 15% of the AAC(2')-Ic 
activity when tested at 200 µM. These data demonstrate the 
high selectivity of the inhibitors towards Eis. 
Crystal Structure of EisC204A-CoA-inhibitor 39 Com-
plex. In order to characterize the mechanism of our Eis 
inhibitors, explain the SAR, and aid in future drug devel-
opment, the crystal structure of Eis in complex with CoA 
and inhibitor 39 was determined at the resolution of 2.1 A 
(FIG. 2 and Table 3). 
TABLE 3 
X-ray diffraction data collection and refinement statistics 
for the EisC204A-CoA-inhibitor 39 ternary complex structure. 
Data collection 
Space group 
Number of monomers per asymmetric unit 
Unit cell dimensions 
a, b, c (A) 
a, 13, y (0 ) 
Resolution (A) 
Ila 
Completeness (%) 
Redundancy 
Rmerge 
Number of unique reflections 
Structure refinement statistics 
Resolution (A) 
R(%) 
Rfree (%) 
Bond length deviation (rmsd) from ideal 
(A) 
Bond angle deviation (rmsd) from ideal (0 ) 
Ramachandran plot statisticsb 
% of residues in most allowed regions 
% of residues in additional allowed regions 
% of residues in generously allowed regions 
% of residues in disallowed regions 
R32 
175.2, 175.2, 122.3 
90, 90, 120 
50.0-2.1 (2.14-2.10)" 
16 (2.1) 
95.8 (97.7) 
3.9 (3.8) 
0.08 (0.50) 
37,907 
40.0-2.1 
19.4 
21.9 
0.006 
1.35 
93.8 
6.2 
0.0 
0.0 (0 residues) 
aNumbers in parentheses indicate the values in the highest-resolution shell. 
bindicates Procheck statistics (23). 
22 
aniline moiety is stacked between the rings of Phe84 and 
Trp36, with the methoxy group surrounded by the nonpolar 
stem oftheArg37 side chain, Phe84, Trp13, and Val40. This 
explains why removing the aniline ring resulted in a loss of 
activity for compounds 12, 15, 16, and 22-26. The quinoxa-
line moiety stacks against Phe24, a residue that interacts 
with tobramycin, as previously observed in a crystal struc-
ture of an Eis-TOB complex. The NH group of the quinoxa-
line ring on the side of the sulfonamide forms a hydrogen 
10 bond with the carboxyl group of Asp26 (N---0 distance of 
2.9 A) and the oxygen of the sulfonamide forms a hydrogen 
bond with the main chain nitrogen of Ile28 (0-N distance 
of3.0 A). Our SAR studies showed that compounds with an 
N-methyl group of the sulfonamide moiety displayed higher 
15 Eis inhibitory activity than those with an NH group, which 
can be rationalized by the optimal van der Waals interaction 
of the methyl with Trp36 (the distance between the methyl 
C atom and the closest C of the Trp36 side chain is 3.6 A). 
Eliminating the methyl group would abolish this interaction, 
20 putting a polar NH in a hydrophobic environment, likely 
destabilizing binding (5 vs 37, 30 vs 29, 31 vs 33, and 32 vs 
35). Replacing the aniline ring with an N-aryl piperazine 
(compounds 17-21) resulted in a loss of Eis inhibitory 
activity when compared to the aniline ring. As described 
25 above, this part of the molecule is snugly fit in a hydrophobic 
pocket, which is too small to accommodate these larger 
groups. The ortho position of the aniline ring is flanked by 
the C-terminal residue Phe402 and it abuts Phe84, explain-
ing why an ortho substitution, as in compound 36, resulted 
30 in a loss of Eis inhibitory activity. A bulky group such as 
n-butyl ( 44) or t-butyl ( 45) in meta position of the aniline 
ring would clash with Arg3 7 that is structurally fixed by Jt-Jt 
stacking with the inhibitor, explaining the poor inhibitory 
activity of these two compounds. A meta,meta-disubstitution 
35 ( 40) resulted in a dramatic decrease in activity as the second 
substituent would clash with the side chain of Met65. 
Electron-donating groups such as methoxy (39) or a naph-
thalene ring ( 46) increase the Jt-Jt interaction of the aniline 
ring with Phe84 and Trp36, explaining their stronger inter-
40 actions in the AG-binding pocket of Eis. However, combin-
ing the two substituents in compound 47 led to a loss of 
activity, as both substitutions cannot be sterically accom-
modated. 
The overall conformation of Eis in complex with the 
45 inhibitor is similar to the previously reported crystal struc-
ture. A notable conformational difference is that a part of a 
loop (residues 28-30) and a helix (residues 31-37) are shifted 
towards the inhibitor relative to their conformation in the 
structure without the inhibitor by 1-1.5 A, apparently in an 
50 induced-fit fashion, to maximize steric contacts. The indole 
ring ofTrp36 in this helix is rotated by -40°, maximizing the 
stacking with the aniline ring and other interactions, as 
explained above. These small, but significant conforma-
tional changes likely precluded us from obtaining a correct 
55 model of a bound inhibitor by prior extensive computational 
docking simulations. In summary, the crystal structure of the 
EisC204A-CoA-inhibitor 39 complex allowed explanation 
of biochemical and biological data and provides a solid 
foundation for further rational structure-based development 
60 of Eis inhibitors. Although sulfonamide 46 was the best compound in 
biochemical and biological studies, it did not co-crystallize 
with Eis. Therefore efforts were focused on compound 39, 
the second best compound. The crystal structure demon-
strates that inhibitor 39 is bound in the part of the AG-
binding pocket that is formed by the N-terminal domain of 65 
Eis. The inhibitor is apparently stabilized in the bound state 
In conclusion, the biochemical, biological, and structural 
studies described in this example provide a proof-of-prin-
ciple of the activity of Eis inhibitors as promising KAN 
adjuvants. The SAR combined with the co-crystal structure 
will guide future development of these compounds for their 
clinical use against MDR- and XDR-TB. 
by numerous hydrophobic interactions. Specifically, the Synthesis and Characterization of Sulfonamides 29-47. 
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were re-tested (Table 4 and Table 5). Of these 617 mol-
ecules, 133 showed reproducible inhibition of Eis enzymatic 
activity in the same single-point HTS assay. Thirty-six of 
these 133 compounds were chosen for further testing in 
Sulfonamides 29-47 were synthesized in two chemical 
steps (Table IA). A detailed description of the synthetic 
procedures as well as characterization by 1 H, 13C NMR, and 
mass spectrometry can be found in the Materials and Meth-
ods Section. 
Chemical Library Screening for Eis Inhibitors, Hit Vali-
dation, Inhibition Kinetics, and Inhibitor Selectivity. 
Acetyltransferase inhibition was assessed by monitoring 
the absorbance at 412 nm (E412=14140 M- 1 cm- 1) of a 
compound generated by the reaction between the free thiol 
group ofCoAreleased during acetylation and 5',5-dithiobis-
(2-nitrobenzoic acid) (DTNB), as described in the Materials 
and Methods and Table 2. 
5 dose-response assays, based on the potency of their inhibi-
tion of Eis in the HTS assay and the structural diversity of 
their chemical substituents (R1 and R2 groups). In a previous 
study of Eis inhibitors evaluating fewer molecules, we 
demonstrated that active compounds contained (i) a group 
Mycobacterial MIC Determination by Alamar Blue. 
10 that may become positively charged, usually an amine, or 
(ii) an aromatic group. The presence of either of these groups 
was therefore also a criterion for selection of compounds for 
dose-response testing. Additionally, four analogues that 
were not a part of the original library were included, but 
The MIC values for KAN in the absence and presence of 
Eis inhibitors 29-47 was determined against KAN-sensitive 
and KAN-resistant Mtb strains H37Rv and K204, respec-
tively, as described in detailed in the Materials and Methods 
Section and Table 2. 
15 which contained the same structural core (Table 4). This 
process yielded a group of forty molecules, for which IC50 
values were determined against purified Eis. The effect of 
these compounds on KAN MIC for KAN-susceptible 
(H37Rv) and KAN-resistant (K204) Mtb strains (Table 5), 
Crystallization and Structure Determination of the 
EisC204A-CoA-Inhibitor 39 Complex. 
20 were also measured as described in the two following 
Inhibitor 39 was soaked into rhombohedral crystals of 
EisC204A in complex with CoA upon an elaborate solvent 
exchange procedure as described in details in the Materials 
and Methods. Data were collected and the structure was 25 
determined by molecular replacement using the previously 
published Eis structure (PDB code 3R1K) as the initial 
model. The inhibitor was built unambiguously into a strong 
F 0 -F c electron density as detailed in the Materials and 
Methods, FIG. 2, and Table 3. 
Example 2 
30 
Disclosed herein are inhibitors of Eis that could be 
co-administered with KAN in order to prevent inactivation 35 
by Eis in Mtb. Here, the identification as well as the 
biochemical and biological characterization of several 
potent inhibitors of Eis that were able to restore the anti-
bacterial activity of KAN in a KAN-resistant strain, Mtb 
K204 are reported. To clarify in atomic details the mode of 40 
action of these compounds and their structure-activity-rela-
tionships, crystal structures of EisC204A in complex with 
CoA and two of these inhibitors were also determined. A 
123,000-compound high-throughput screen (HTS) yielded 
several small-molecule Eis inhibitors that share a sulfonyl 45 
isothiazole scaffold. These were investigated for their struc-
ture-activity relationships. Crystal structures of Eis in com-
plex with two potent inhibitors show that these molecules 
are bound in the conformationally adaptable aminoglycoside 
binding site of the enzyme, thereby obstructing binding of 50 
KAN for acetylation. Importantly, several Eis inhibitors, 
when used in combination with KAN against resistant Mtb, 
efficiently overcome KAN resistance. This approach paves 
the way toward development of novel combination therapies 
against aminoglycoside-resistant TB. 55 
High-Throughput Screening Leads to the Identification of 
a Promising Eis Inhibitor Scaffold. 
In order to identify Mtb Eis inhibitors, HTS of molecular 
libraries comprising 123,000 structurally diverse small mol-
ecules using a previously reported Eis acetylation assay in 60 
the miniaturized format was performed (FIG. 3). The initial 
HTS assay was performed using the aminoglycoside neo-
mycin B (NEO) as a substrate, which was selected over 
KAN to maximize the signal to noise ratio under the HTS 
conditions. However, KAN was used in all post-HTS assays, 65 
since it is the clinically relevant aminoglycoside. The HTS 
yielded 617 hits containing a sulfonyl isothiazole core that 
sections. 
TABLE 4 
Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
Main 
scaffold 
2 
F 
Cl 
a 
b 
d 
US 10,208,000 B2 
25 26 
TABLE 4-continued TABLE 4-continued 
Structures of Compounds of Example 2. Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
The 617 molecules tested are noted in Table 6. 
10 
sx-r-ta 
\ j 
f sx-t() 
15 
20 
,x-r-p qc, g 
# 25 sx-t(~ qfu h 30 ox-t()-() 
35 
rn x-r-N 
40 
R, - r-NH(CH,);X 
45 nx+<=o 
,x-r-0 UX+No 50 
0 
OX-r-Nb 
55 nx-t() 
H- r-N(CH,CH,l, 
60 
«x-t()-
,x-tCo 
65 
Vi X- t{JN_/ 
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Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
>SX-r-()_p 
nx-r-()-0 
,sx-r-()-q 
"x-K) 
,;,x-t-0-c, 
,sx-t-0-J 
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Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
.Sc X- r--d=OCH; 
0\ 
sox-r-Q-\_ 
.,.,x-r-{J 
S<X-r-0 
,sx-r-() 
.ssx-r-()-
nx-r-()\ 
.,u,-r-<) 
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44: Y- CH3 
45: X - z - CH3 
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,n-K--< 
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>OY- HNO 
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Structures of Compounds of Example 2 
The 617 molecules tested are noted in Tab;e 6. 
R 
- LNr-\N-X 2-ry 
y 
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Structures of Compounds of Example 2 
The 617 molecules tested are noted in Table 6. 
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Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
81: X -Y- CH2 CH3 
83: x-
84:X-
85: x-
86: x-
87: x-
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TABLE 4-continued 
Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
Note: When not specified, W, X, Y, and z - H 
89: W - X - Y - Z - H 
90: W- CH3 
91: W- F 
92: W- Cl 
93: W- OCH3 
94: W - OCH2 CH3 
95: X - Cl 
96: X - Br 
97: X - OCH3 
98: Y- CH3 
99: Y - CH2CH3 
100: Y- F 
101: Y- Cl 
102: Y- OCH3 
103: Y - OCH2CH3 
104: Y- OCH(CH3)o 
105: Y - N(CH3 )2 
106: W-X- OCH3 
107: W - OCH3 , X - OCH2 CH3 
108: W - CH3 , Y - N(CH2CH3)o 
109: W - OCH3 , Y - Br 
110: W-Z- OCH3 
111: X, Y- OCH2 0 
116: x-~ 
117:X- r-0--SCH; 
118: x- r-Qo 
0) 
UOR;-r-~'° 
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R,-r-~,lX R,-r-= 
137: X - CH3 10 138: X - CH2CH3 
t-0 139: X - (CH2 )2 CH3 120:X- 140: X - CH(CH3)o 141: X - CH(CH3)CH2 CH3 142: X - C(CH3h 
15 143: X - (CH2 )2 CH(CH3)o 
t-Q-0 144: X - (CH2 )2 0CH3 145: X - (CH2 ) 30CH3 146: X - (CH2 ) 30CH2 CH3 121:X- 147: X - (CH2 ) 30CH(CH3)o 
o_) 20 R,+--~ 122:X- mx-t--<1 25 D/x R,- r-~ y 30 mx-t--0 
~M 
35 nox-t-D 
123:X-
131:X-~ 40 t(_;M 124:X-
r---0--132:X-45 
kQM 125:X- 133:X- r-q 50 
~ 
~M 
55 
134:X-
126:X-
60 
mx-k:_/ M mx-tg 
65 \ j 
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Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
x y 
N~, tNH-
Note: When not specified, X, Y, and Z - H 
199: X - Y - Z - H 
200: X - CH3 
201: Y - CH3 
202: Y- Cl 
203: Y - Br 
204: Z - CH3 
V*Y tNH- Z 
US 10,208,000 B2 
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Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
162:X-
10 
15 
161:X-
20 
162:X-
25 
30 
163:X-
35 
40 
164:X-
45 
Note: When not specified, V, W, X, Y, and Z - H 
165: X - F 
166:X-Cl 
148: V- CH3 
149: V - CH2CH3 
150: V- F 
151: V-Cl 
152: V- Br 
153: V- OCH3 
154: W - CH2 CH3 
155: W- F 
156: W- Cl 
157: W- SCH3 
158: X - CH3 
159: X - CH2CH3 
160: X - CH(CH3h 
50 
55 
60 
65 
167: X - OCH3 
168: X - OCH2CH3 
169: V-W- CH3 
170: V - CH3, W - Cl 
171: V-W- OCH3 
172: V - X - CH3 
173: V-CH3, X -F 
174: V-CH3, X -Cl 
175: V-X - F 
176: V-F, X -Br 
177: V-Cl, X- CH3 
178: V - X - OCH3 
179: V - Y - CH3 
180: V - CH3, Y - Cl 
181:V-Y-F 
182: V - OCH3, Y - CH3 
183: V - OCH3, Y - Cl 
184: V-Y-OCH3 
185: V -Y - OCH2CH3 
186: V-Z -CH3 
187: V - CH3, Z - CH2CH3 
188: W-X- CH3 
189: W- CH3,X - Br 
190: W- Cl, X -CH3 
US 10,208,000 B2 
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Structures of Compounds of Example 2. 
The 617 molecules tested are noted in Table 6. 
191: W - Cl, X - OCH3 
192: W - X - OCH3 
193: W, X - OCH2 0 
194: W-Y- CH3 
195: W - Y - C02 CH3 
196: W - Y - OCH3 
197: V - X - Z - CH3 
198: V - OCH3 , X - Cl, Y - CH3 
TABLE 5 
Structures of the 41 Eis inhibitors with sulofnyl scaffold 
for which IC50 against pure Eis enzyme and MIC values 
against strains H36Rv and K204 Mtb have been evaluated 
Main 
scaffold 
2 
F 
Cl 
10 
15 
20 
25 
a 30 
35 
b 
40 
45 
50 
d 
55 
e 60 
65 
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TABLE 5-continued 
Structures of the 41 Eis inhibitors with sulofnyl scaffold 
for which IC50 against pure Eis enzyme and MIC values 
against strains H36Rv and K204 Mtb have been evaluated 
(YCl 
2C 
sx-t() 
,x-tp 
sx-t(~ 
nx-tNCo 
f 
g 
h 
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Structures of the 41 Eis inhibitors with sulofnyl scaffold 
for which IC50 against pure Eis enzyme and MIC values 
against strains H36Rv and K204 Mtb have been evaluated 
UX-r-No 
nx-t() 
c,x-t()-
,;x-t{:)_/ 
nx-t()-0 
33: x~ 
35: x~ 
36: x~ 
<SY-t() 
s,v-k~ 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
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TABLE 5-continued 
Structures of the 41 Eis inhibitors with sulofnyl scaffold 
for which IC50 against pure Eis enzyme and MIC values 
against strains H36Rv and K204 Mtb have been evaluated 
81: X ~ Y ~ CH2CH3 
87:X~ Y~H 
~o 
89:X~ ~ , Y~H 
139: X ~ (CH2)oCH3, Y ~ H 
Inhibitors with IC50 & MIC: 3i, 6b, 7b, 8a, 8e, llc, 12e, 13a, 13e, 13g, 13i, 14c, 15e, 15f, 
17i, 33a, 35e, 35g, 35h, 35i, 36d, 37b, 37d, 46a, 46b, 46c, 46h, 52i, 62i, 81 b, 81g, 87b, 
89b, 112b, 112i, 115i, 116i, 139b, 139e, 139i 
Structure-Activity Relationship (SAR) Studies. 
Various R1 and R2 side-chains in the identified sulfonyl 
isothiazole scaffold (Tables 4-6), were explored to improve 
anti-Eis potency in vitro. 
us 10,208,000 B2 
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Based on the 617 initial HTS hit molecules, we first drew cyclohexyl moiety, or a benzyl functionality did not effi-
several unambiguous conclusions about the desirable struc- ciently inhibit Mtb Eis. Table 6 is a summary of Eis activity 
ture of the R2 side-chain. Most of the compounds for which of compounds tested against enzyme and, in some instances, 
R2 contained an aromatic ring, a branched alkyl group, a Mtb. 
TABLE 6 
Eis activity of compounds tested against purified enzyme and/or Mtb. 
Table 6 
Cpd a b D f g h Cpd A B c d f g h 
x x x x 104 x x x x 
2 x x x 105 x 
D-- DODD 106 x 
4 D-- 107 x 
x D-- 108 x 
DOD 109 x 
7 DOD D-- 110 x 
DDx D-- DOD 111 x x x x x 
9 x D-- 112 x Dxx x x DDx 
10 DOD 113 x D--
11 ooDD D-- D-- 114 x 
12 DODD 115 Dxx 
13 DOD DOD DOD DDx 116 Dxx 
14 x DDx 117 x 
15 D-- DDx DDx 118 x 
16 x D-- 119 x x x x x 
17 x x D-- DDx 120 x x x x x 
18 x 121 x x x x x 
19 x x x 122 x x x 
20 x 123 x 
21 x x x x x 124 x 
22 x x x x x 125 x 
23 x 126 x x xx x x 
24 x 127 x 
25 x 128 x D-- x x 
26 x x 129 D-- x D-- x x 
27 x x 130 x x x 
28 D-- x x 131 x x xx 
29 x 132 x x 
30 x 133 x x x 
31 x x x x x 134 x 
32 x 135 x x 
33 DDx 136 x 
34 D-- D-- 137 x 
35 x D-- x Dxx DOD DOD DOD 138 D--
36 DODD 139 x Dxx Dxx x Dxx 
37 DOD Dxx 140 D-- D-- x 
38 D-- D-- D-- D-- 141 x x x 
39 x x x x x x 142 x x 
40 D-- D-- D-- x x x x 143 x D-- x x xx x 
41 D-- D-- D-- D-- D-- D-- 144 x x D-- x DOD x D--
42 D-- D-- 145 x x x x 
43 x D-- 146 x x x x x 
44 x D-- D-- D-- D-- D-- 147 x x x x x 
45 x D-- D-- D-- x 148 x x x x x x 
46 DDx DDx DOD D-- D-- DDx D-- 149 x x x x xx 
47 x D-- D-- 150 x x x x x 
48 DOD 151 x x x 
49 D-- 152 x x x 
50 D-- 153 x 
51 x 154 x xx 
52 x DOD 155 x x x 
53 D-- 156 x x 
54 D-- 157 x xx 
55 x 158 x x 
56 D-- 159 x x x x x 
57 x D-- 160 x 
58 D-- 161 x x x 
59 x D-- D-- D-- D-- x x D-- 162 D--
60 x D-- D-- x D-- x D-- 163 x 
61 x D-- D-- D-- D-- x D-- D-- 164 x x x 
62 x DDx 165 x x x x 
63 x x D-- D-- D-- 166 x x 
US 10,208,000 B2 
45 46 
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Eis activity of compounds tested against purified enzyme and/or Mtb. 
Cpd 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
a 
x 
x 
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Table 6 
h 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Cpd A 
D-- 167 
x 168 
x 
x 
x 
x 
169 
170 
171 
172 x 
173 x 
174 x 
175 x 
176 x 
177 x 
178 x 
179 x 
D-- 180 x 
x 
x 
x 
x 
x 
x 
x 
x 
181 x 
182 
183 
184 x 
185 
186 
187 x 
188 x 
189 x 
190 x 
191 
192 
193 
194 x 
195 
196 
197 x 
198 x 
B 
x 
x 
x 
x 
x 
x 
x 
x 
x 
199 x 
x 
x 
x 
x 
200 x 
201 
202 
203 
204 
205 x 
206 x 
x 
x 
x 
Empty box indicates that the combination of R1 (letter) and R2 (number) did not exist in the tested library. 
x indicates that the compound did not inhibit Eis purified enzyme in the initial HTS. 
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x x 
xx xx xx 
x x 
x 
xx 
x 
x x x xx x 
x x x x x 
x x 
x 
x 
x 
xx xx xx 
x x 
x x 
xx 
x x x x x 
x x 
x 
x x x x x 
x 
x 
x 
x x 
x 
x 
x 
x x 
xx x 
x x 
x 
x x x 
x x 
x x x 
x 
x 
x 
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x 
x 
xx x 
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x 
x x 
x 
D-- indicates that the compound inhibited Eis purified enzyme in the initial HTS, but was not pursued for determination of IC50 values. 
Dxx indicates that the compound inhibited Eis purified enzyme in the initial HTS, but was found to not be a strong Eis inhibitor after determination 
of its IC50 and also did not affect Mtb growth. 
DDx indicates that the compound inhibited Eis purified enzyme in the initial HTS and was found to be a moderate to good Eis inhibitor after 
determination of its IC50, but did not affect Mtb growth. 
DOD indicates that the compound inhibited Eis purified enzyme in the initial HTS and was found to be a moderate to good Eis inhibitor after 
determination of its IC50, and was also found to affect Mtb growth. 
DODD indicates compounds that we selected to purchase that were not in our initial HTS. These compounds were found to be a moderate to good 
Eis inhibitor after determination of its IC50 and were also found to affect Mtb growth. 
Compounds that did not efficiently inhibit Mtb Eis are 
indicated by x in Table 6. Among the forty compounds that 
were pursued beyond the dose-response assay, compounds 
containing R2 groups 8, 13, 15, 35, 46, and 81 inhibited Eis 
in vitro when combined with multiple R1 substituents (as 
indicated by DDx and DOD, respectively, in Table 6) while 
other R2 groups were shown to inhibit Eis in dose-response 
assays when in combination with only one of the possible R1 
substituents (6b, 7b, llc, 12e, 14c, 17i, 33a, 36d, 37b, 52i, 
62i, and 112i). Overall, two large families ofR2 substituents 
emerged as potential potent inhibitors of Eis: (i) compounds 
with R2 containing two nitrogen atoms separated by three 
carbon atoms (structures 3, 6-8, 11-15, and 17), particularly 
compounds with large bulky groups or a cyclohexyl ring 
attached to the extended nitrogen atom were most often 
inhibitory; and (ii) compounds containing an R2 group with 
two nitrogen atoms separated by two carbon atoms also 
efficiently inhibited Eis (structures 33, 35-37, and 112). In 
55 this series of molecules, only compounds with a nitrogen 
atom located in a cyclohexyl ring were inhibitory. 
We next explored the effect of the R1 substituents on Eis 
inhibition. Upon initial inspection of the 617 HTS hits, the 
60 identity of the R1 substituent appeared to have little effect on 
their Eis inhibitory activity. However, when analyzing these 
side chains statistically, patterns emerged. The p-fluorophe-
nyl group (b) had the highest percentage (34%) of com-
pounds inhibiting Eis in the initial HTS; this was followed 
65 closely by the p-methylphenyl group (e, 33%) and the 
m,p-dimethylphenyl group (i, 30%), suggesting that these 
three groups as R1 substitutions have a better chance of 
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contributing positively to Eis inhibition. The next best R1 
substituent was the p-chlorophenyl group (c) with 27% of 
the compounds within this group displaying inhibition of 
Eis. The m-chlorophoenyl group (g) and p-anisole group (d) 
were next with 19% and 18% of their compounds displaying 
Eis inhibition, respectively. Finally, with 13%, 12%, and 9% 
of compounds showing Eis inhibition were compounds 
containing the p-isopropylphenyl (f), the m-bromophenyl 
(h), and the phenyl (a) group as Ri, respectively. 
Having established general trends for the R1 and R2 10 
substituents by analyzing the data from Table 6, we next 
focused on the measured in vitro potency (IC50) of the forty 
selected compounds (Table 7). 
Several trends consistent with those established above 
emerged from these quantitative data. With the exception of 15 
compound 112i, mono-substituted R2 amine substituents 
comprised of a straight alkyl chain (139b, 139e, 139i), an 
aromatic ring (87b, 89b, 112b ), or an amide functionality 
(115i, 116i) did not inhibit purified Eis. Compounds with R2 
substituents containing a diamine separated by two carbon 20 
atoms with the second amine present in a cyclohexyl ring all 
displayed good to moderate Eis inhibition. However, no 
conclusion could be formed as to what type of cyclohexyl 
ring was best, an unsubstituted (33a), a morpholino (35e, g, 
h, and i), or a piperazinyl (36d or 37b) ring, as most IC50 25 
values were similar for these compounds. Compound 13i 
with a diamine separated by three carbons at the R2 position 
and the m,p-dimethylphenyl group at the R1 position was 
found to be the most potent Eis inhibitor (IC50=0.054±0.002 
µM). Interestingly, compound 46b with a cyclohexyl ring 30 
directly attached to the core scaffold followed by a second 
piperazine ring in the para-position was found to be the 
second best Eis inhibitor (IC50=0.092±0.021 µM). These 
results indicate that both a rotationally free alkyl chain (as in 
compound 13i) or cyclically restricted alkyl linkers could be 35 
useful in designing Mtb Eis inhibitors. 
TABLE 7 
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TABLE 7-continued 
Eis inhibition IC50 values of tested compounds and 
tbe effect of tbe compounds on kanamycin A MIC values 
against H37Rv and K204 Mtb strains. 
H37Rv K204 
Concentration MIC KAN MIC KAN 
Cpd ICso (µM)" tested (µM/ (µg/mL)" (µg/mLl 
46c 0.109 ± 0.022 10.9 0.625 2.5 
46h 0.135 ± 0.031 13.5 0.625 
52i 0.580 ± 0.096 58 0.625 2.5 
62i 0.386 ± 0.080 38.6 0.625 
81b 1.25 ± 0.22 124.8 0.625 2.5-5 
81g 1.42 ± 0.42 142.3 0.625 2.5 
87b >200 20 1.25 10 
89b >200 20 1.25 10 
112b >200 20 0.625 10 
112i 0.621 ± 0.229 62.1 0.625 
115i >200 20 0.625 10 
116i >200 20 1.25 10 
139b >200 20 0.625 10 
139e >200 20 1.25 10 
139i >200 20 1.25 10 
aTbe IC50 values in the Eis acetyltransferase assay. 
b At these concentrations, these compounds did not inhibit the growth ofH37Rv or that of 
K204 Mtb, when tested in the absence of KAN. 
"KAN MIC values for H37Rv Mtb in the absence (first line) and in the presence of each 
compound at the specified concentrations. 
dSame as c, but for K204 Mtb. 
To establish whether the inhibitors identified were specific 
to Eis over AACs from other families, compounds 46b and 
46c were tested against AAC(6')-Ie/APH(2")-Ia from 
Staphylococcus aureus, AAC(3)-IV from E. coli, and AAC 
(2')-Ic from Mtb. Under optimal reaction conditions for each 
enzyme, no inhibition by either compound was observed 
with any of these AACs. These data demonstrate that the 
compounds are exquisitely selective for Mtb Eis over other 
AA Cs. 
Eis Inhibitors Abolish Eis-Mediated Resistance of Mtb to 
KAN. 
Having identified inhibitors of purified Mtb Eis enzyme, 
Eis inhibition IC50 values of tested compounds and 
tbe effect of tbe compounds on kanamycin A MIC values 
against H37Rv and K204 Mtb strains. 
40 we next set to determine their activity in cellulo. Mycobac-
Concentration 
Cpd IC50 (µM)" tested (µM/ 
3i 0.120 ± 0.035 12 
6b 0.152 ± 0.045 15.2 
7b 0.102 ± 0.034 10.2 
Sa 2.85 ± 0.26 184.5 
Se 0.200 ± 0.036 20 
11c 0.238 ± 0.089 23.8 
12e 0.183 ± 0.043 18.3 
13a 2.82 ± 0.21 282.3 
13e 0.331 ± 0.071 33.1 
13g 0.234 ± 0.060 23.4 
13i 0.054 ± 0.002 5.42 
14c 0.112 ± 0.008 11.2 
15e 0.535 ± 0.045 53.5 
15f 0.148 ± 0.016 14.8 
17i 0.232 ± 0.038 23.2 
33a 0.123 ± 0.023 13.2 
35e >200 20 
35g 2.49 ± 0.49 100 
35h 3.23 ± 0.99 100 
35i 0.985 ± 0.190 98.5 
36d 0.152 ± 0.031 15.3 
37b 0.657 ± 0.105 65.7 
37d >200 20 
46a 0.432 ± 0.057 43.2 
46b 0.092 ± 0.021 9.21 
H37Rv 
MIC KAN 
(µg/mL)" 
1.25 
0.625 
0.625 
0.625 
0.625-1.25 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625-1.25 
0.625-1.25 
0.625-1.25 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625 
0.625-1.25 
0.625-1.25 
0.625-1.25 
K204 
MIC KAN 
(µg/mLl 
10 
1.25 
2.5 
2.5 
2.5-5 
1.25 
2.5 
2.5 
2.5 
2.5-5 
10 
2.5 
2.5 
2.5 
2.5-5 
2.5-5 
5-10 
10 
45 
50 
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teria are notorious for their waxy cell wall that is difficult to 
penetrate for small molecules. Therefore, we anticipated that 
not all of the compounds that exhibited inhibition of purified 
Eis would be effective in cell cultures. We measured the 
effect of the forty selected compounds (at a concentration of 
100-fold higher than their IC50 values) on KAN MIC values 
against Mtb K204, a KAN-resistant strain bearing a clini-
cally observed eis promoter mutation known to upregulate 
Eis production (Table 7). In the KAN-susceptible H37Rv 
strain, the MIC value of KAN is 1.25 µg/mL, whereas in the 
KAN-resistant K204 strain, the MIC value of KAN is 10 
µg/mL. As expected, compounds that did not inhibit purified 
Mtb Eis (35e, 37d, 87b, 89b, 112b, 115i, 116i, and 139b, e, 
and i) did not overcome resistance to KAN in Mtb K204. 28 
of the remaining 30 Eis inhibitors resulted in at least a 2-fold 
reduction in KAN MIC against Mtb K204, with two of these 
compounds, 3i and l lc, lowering KAN MIC 8-fold, down to 
the level of the KAN-susceptible H37Rv strain. Not unex-
60 pectedly, among very potent inhibitors of the enzymatic 
activity of Eis in vitro, there were some compounds that had 
little or no effect at sensitizing the resistant Mtb strain K204 
to KAN. The compounds that reduced the MIC value of the 
KAN-resistant Mtb strain 4-fold had IC50 values that ranged 
65 from 0.102±0.034 to 3.23±0.99 µM, emphasizing the notion 
that in vitro and in cellulo or in vivo activities need not be 
perfectly correlated. 
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Crystal Structures of Eis-Inhibitor Complexes Reveal the 
Inhibition Mechanism. 
To elucidate the mechanism of Eis inhibition by the 
sulfonyl isothiazole-containing compounds, rationalize the 
observed SAR, and guide future rational inhibitor design, 
2.2 A-resolution crystal structures of Eis in complex with 
CoA and inhibitors 13g and l le (FIGS. 4a,c) were deter-
mined, which displayed both potent inhibition of Eis acety-
lation in vitro and the KAN resistance abolishing effect in 
the Mtb cultures. Both inhibitors and their chemical features 
were clearly distinguishable and modeled into strong F O -F c 
electron density (FIG. 4b,d). The only exception was the 
1,2,3,4-tetrahydroisoquinoline (THQ) group of l le, for 
which only partial electron density was observed (FIG. 4d), 
likely due to a somewhat dynamic behavior of this highly 
hydrophobic group in a partially polar environment, as 
allowed by the flexible diamine linkage. No other significant 
difference electron density that could be attributed to a 
bound inhibitor was observed elsewhere. Both inhibitors 
exhibited high steric complementarity with the Eis surface. 
The binding site for both inhibitors overlapped with the 
aminoglycoside substrate-binding site, as was recently 
established by the structure ofMtb Eis in complex with CoA 
and tobramycin. In addition, the R2 groups of both inhibitors 
reached the C-terminal carboxyl group of Eis, which was 
proposed to serve as the general base in the acetyl transfer 
reaction. Therefore, these crystal structures indicate that the 
inhibitors block access of aminoglycosides to the active site 
of the enzyme. Explaining the critical role of the sulfonyl 
isothiazole core, this group is bound in the same location and 
orientation in both Eis-inhibitor structures (FIG. 4b,d). 
Remarkably, despite the nearly identical positions of this 
group, there are differences in how this group interacts with 
the protein for the two inhibitors. These differences are due 
50 
charged ring nitrogen of R2 occupies nearly the same loca-
tion where it forms a salt bridge with the carboxyl group of 
Glu401 in both structures. Besides this interaction, R2 group 
of compound 13g makes steric and weak electrostatic inter-
actions with His119, Ser121, Glu401, and the C-terminal 
carboxyl group (weakly electrostatically interacting with the 
stem N) on one side and making water-mediated steric 
interactions with region 26-31 on the other side. In contrast, 
for the R2 of the compound l le: while the interactions with 
10 one face of this group are made with the same amino acid 
residues, the other face interacts directly through hydropho-
bic and steric interactions with the region 26-31, which is in 
a different conformation. Most prominently, the side chain 
of Asp26 is flipped to interact with the stem, and Phe24 
15 orthogonally stacks against the double ring. Because the R1 
group abuts the hydrophobic wall, whereas R2 group points 
towards the more extended end of the substrate binding 
channel, there is more variability in both the identity and the 
size of R2 substituents, as exhibited in the list of effective R2 
20 groups (Table 4). 
Discussion 
While it has been met with initial skepticism, target-based 
rational drug design is now gaining momentum and is 
widely used in industrial and academic drug discovery 
25 pipelines, due to advances in HTS technology, robust assay 
development practices and availability of large and diverse 
chemical libraries. Prominent examples of successful ratio-
nal drug design are HIV protease inhibitors ritonavir and the 
anticancer drug Gleevec. Here, we report the discovery and 
30 initial preclinical development of novel first-in-class sulfo-
nyl isothiazole inhibitors of a unique acetyltransferase Eis 
from Mtb as an agent that overcomes one mechanism of 
resistance to KAN in Mtb. Among the diverse pool of 
compounds tested, we found agents that we validated as 
35 potent inhibitors of Eis both in the test tube and in the 
relevant Mtb cultures. Potencies in mid-nM range appear to 
be achieved through binding of the compounds via steric 
complementarity, hydrophobic and hydrogen bonding inter-
actions. While one substituent group (R1) is relatively 
to significant induced-fit conformational changes in the 
region spanning residues 26-31 of Eis (FIG. 4b,d), which 
uniquely adapts to bind the two structurally different R2 
groups. For inhibitor 13g (FIG. 4a,b), one of the sulfonyl 
oxygens forms a direct hydrogen bond with the main chain 
amide nitrogen of Phe84 and the ring nitrogen forms a 
water-mediated hydrogen bond with the main chain amide 
nitrogen of Ile28. In this case, the Eis conformation 
resembles that observed in a previously reported crystal 
structure with the aminoglycoside-binding pocket unoccu-
pied. Inhibitor Ile does not make any water-mediated con-
tacts due to a small positional shift of the inhibitor and a 
conformational change of Eis. Instead, the two sulfonyl 
oxygens are at a distance of -4 A, consistent with the 
stabilizing van der Waals and electrostatic interactions. The 
isothiazole ring is sterically sandwiched between the side 50 
chains of Ile28 and Ser83 in one direction and between the 
side chains of Phe24 and Trp36 in the orthogonal direction. 
The R1 groups of the two compounds are almost coplanar 
and fit neatly into a nearly fully nonpolar environment of 
side chains Leu63, Trp13, and Ala33, the aliphatic stem of 55 
Arg37, Met65, and Phe84, explaining the nonpolar phenyl 
ring with small substitutions as effective R1 groups (Table 
40 unchangeable in terms of its size and physico-chemical 
properties, the other group (R2 ) can greatly vary. The crystal 
structures of Eis-inhibitor complexes demonstrate that bind-
ing to variable structures is achieved by conformational 
plasticity of the aminoglycoside-binding site of Eis, which 
45 adapts to different R2 groups, while the R1 group achieves a 
nearly rigid-body fit. Binding of the two inhibitors of Eis 
investigated structurally differs not only in protein confor-
mation, but also in the presence or absence of water-
mediated contacts. 
Aminoglycosides are among the antibiotics of last resort 
for MDR and XDR-TB patients, and resistance to them 
strongly decreases the chances of a favorable treatment 
outcome. The strategy of using KAN in combination with an 
Eis inhibitor is meant not only to overcome KAN resistance 
due to Eis upregulation, but also to curb emergence of new 
resistant strains by mutagenesis of the eis promoter, as such 
mutation would not have survival benefit in the face of 
combination therapy. This study not only validates AAC' s as 
drug targets, but has set an important precedent for HTS-
driven discovery for AACs that cause resistance in clinically 
useful non-TB pathogens, such as AAC(3) and AAC(6') in 
5). Such environment, devoid of hydrogen bond donors or 
acceptors is appropriate for accommodating halogen sub-
stituents, as is the case with Ile and 13g. The halogens can 60 
be accommodated in the para and/or one, but not both meta 
positions. Substitutions at both meta positions would not be 
accommodated, as reflected in the list of potent inhibitors 
(FIG. 3, Table 5), since one of them would clash sterically 
with the side chain of Met65. In contrast with R1 , the 65 
conformations of the R2 groups of the two inhibitors are 
drastically different with one exception-the positively 
Klebsiella pneumoniae (32-34). As with TB, such inhibitory 
agents could play an important role in both overcoming 
existing resistance and curbing the acquisition of resistance. 
In conclusion, we identified potent inhibitors of Eis enzy-
matic activity with resulting sensitization of KAN-resistant 
Mtb cells, in which the resistance to KAN is caused by Eis 
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upregulation. The inhibitors bind in the AG binding pocket 
blocking the access of AGs to the active site of the enzyme. 
The inhibitor binding is accompanied by induced-fit con-
formational changes of the protein. These compounds have 
a great potential for further development as KAN adjuvants 5 
in Mtb. 
Protocols: 
Detailed versions of the abbreviated protocols below are 
provided in the Materials and Methods. 
Protein, Reagents, and Small-Molecule Libraries. 10 
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1.2. Synthesis and Characterization of Sulfonamides Gen-
erated in this Study. 
Synthesis of Compound A. 
The known compound A was prepared following a pre-
viously published protocol. 1 Chlorosulfonic acid (20.53 mL, 
The wild-type Eis from Mtb (4), EisC204A (10), AAC 
(6')/APH(2") (35), AAC(3)-IV (35), and AAC(2')-Ic (4) 
were overexpressed and purified as previously reported, 
with minor modifications. All reagents were purchased from 
Sigma with the exception of Albumin-dextrose-catalase 
(ADC), which was from BD Biosciences. Eis was screened 
at the Center for Chemical Genomics (CCG, University of 
Michigan) against 123,000 compounds from three libraries. 
Compounds were retested as fresh powder samples pur-
chased from ChemDiv. 
15 308.36 mmol) was added to quinoxaline-2,3-diol (5.00 g, 
30.83 mmol). The reaction mixture was then refluxed for 12 
h. After cooling to room temperature, the reaction mixture 
was carefully poured onto ice, filtered, and the precipitate 
was washed with H2 0 (50 mL). The solid was collected and 
Eis Chemical Library Screening and Hit Validation. 
Screening of small-molecule libraries, hit validation, and 
dose response analysis (represented by FIG. 5) were per-
formed as previously described. 
20 recrystallized with toluene to afford A (7 .07 g, 88%) as a 
white solid: 1 H NMR ( 400 MHz, (CD3 ) 2 SO, which matches 
lit.) ll 11.97 (s, lH), 11.94 (s, lH), 7.43 (d, l=l.6 Hz, lH), 
7.30 (dd, 1=8.4, 1.6 Hz, lH), 7.04 (d, 1=8.4 Hz, lH). 
Inhibitor Selectivity. 
Compounds 46b and 46c were tested against three addi-
tional AAC enzymes: AAC(6')/APH(2"), AAC(3)-IV, and 
AAC(2')-Ic at optimal reaction conditions for each enzyme. 
25 
Mycobacterial MIC Determination by Alamar Blue 30 
Assay. 
The assay was done with Mtb strains H37Rv and K204 in 
7H9 broth. Compounds were tested at either lOOx IC50 (if 
known) or 20 µM for their inhibitory effect on Mtb growth 35 
and on KAN MIC in these two strains. 
Crystallization, Diffraction Data Collection, and Structure 
Determination and Refinement of EisC204A-CoA-Inhibitor 
Complexes. 
Bru O I II H 
~ .,,..s'CCNXo N II I I a 
# N O 
H 
General Procedure for the Synthesis of Sulfonamides 
(e.g., Preparation of Compound 29). 
A solution of compound A (0.30 g, 1.15 mmol) and 
4-bromo-N-methylaniline (0.29 mL, 2.30 mmol) in DMF (6 
mL) was stirred at room temperature for 12 h. H2 0 was 
added to the reaction mixture and the formed precipitate was 
Crystals were grown by the hanging drop method and 
then underwent a complex harvesting process. The cryopro-
tectant solution contained 0.5 mM inhibitor. The diffraction 
data were collected at synchrotron beamline 22-ID of the 
Advanced Photon Source at the Argonne National Labora-
tory (Argonne, Ill.) at 100 K. The data were processed and 
the structures were built and refined by previously described 
methods. 
40 filtered and washed with H20 (10 mL) to yield 29 (0.21 g, 
45%) as a purple solid: 1H NMR (400 MHz, (CD3 ) 2 SO) Ii 
12.27 (s, lH), 12.00 (s, lH), 7.55 (app dt, 1=9.6, 3.2 Hz, 2H), 
7.25 (d, 1=9.6 Hz, 2H), 7.24 (s, lH), 7.07 (app dt, 1=9.2, 3.2 
Hz, 2H), 3.09 (s, 3H); 13C NMR (100 MHz, (CD3 ) 2 SO) Ii 
45 155.2, 154.8, 140.4, 131.9, 129.8, 129.3, 128.4, 125.9, 
122.4, 120.2, 115.5, 114.4, 37.7; LRMS rn/z calcd for 
C15H13BrN30 4 S [M+Ht: 410.0; found 410.8. 
Material and Methods 
1. Chemistry 
1.1. General. 
Example 1 50 
All reagents were purchased from commercial sources 
and used without purification. TLC analyses were performed 55 
on silica gel plates (pre-coated on aluminum; 0.20 mm 
thickness with fluorescent indicator UV254) and were visu-
alized by UV or charring in KMn04 stains. 1 Hand 13C NMR 
spectra were collected on 400 MHz NMR spectrometer 
(VARIAN INOVA) using (CD3 ) 2 SO. Chemical shifts are 60 
reported in parts per million (ppm) and are referenced to 
residual solvent peaks. All reactions were conducted under 
nitrogen atmosphere and all yields reported refer to isolated 
yields. The known compound A was characterized by 1 H 
NMR and is in complete agreement with sample reported 65 
elsewhere. All new compounds were characterized by 1 H, 
13C NMR, and mass spectrometry. 
Bru O I II H 
~ .,,..s'CCNXo N II I H O 
# N O 
H 
Preparation of Compound 30. 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 4-bromoaniline (0.39 g, 2.30 
mmol), and DMF (6 mL) were used to afford compound 30 
(0.21 g, 47%) as a light yellow solid: 1H NMR (400 MHz, 
(CD3 ) 2 SO) Ii 12.17 (s, lH), 12.09 (s, lH), 10.49 (br s, lH), 
7.51 (d, l=l.6 Hz, lH), 7.45 (dd, 1=8.0, 1.6 Hz, lH), 7.41 
(app dt, 1=9.6, 2.8 Hz, 2H), 7.19 (d, 1=8.0 Hz, lH), 7.04 (app 
dt, 1=9.6, 2.8 Hz, 2H); 13C NMR (100 MHz, (CD3 ) 2 SO) Ii 
155.2, 154.9, 137.1, 133.1, 132.1, 129.5, 125.9, 121.9, 
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121.5, 116.2, 115.6, 113.7, 113.6; LRMS m/z calcd for 
C14H11N3 0 4 SBr [M+Ht: 396.0; found 396.8. 
Q o 
_J'CC~Xo N II I H O 
# N O 
H 
Preparation of Compound 31. 
10 
As described for the synthesis of compound 29, com-
poundA (0.30 g, 1.15 mmol), aniline (0.21 mL, 2.30 mmol), 15 
and DMF (6 mL) were used to afford compound 31 (0.22 g, 
61 % ) as a light yellow solid: 1 H NMR ( 400 MHz, 
(CD3 ) 2 SO) ll 12.15 (s, lH), 12.08 (s, lH), 10.32 (br s, lH), 
7.53 (s, lH), 7.44 (d, J=8.4 Hz, lH), 7.24-7.17 (m, 3H), 7.08 
(d, J=8.4 Hz, 2H), 7.02 (t, J=7.2 Hz, lH); 13C NMR (100 20 
MHz, (CD3 ) 2 SO) ll 155.2, 154.9, 137.6, 133.5, 129.3, 129.2, 
125.8, 124.0, 121.5, 119.9, 115.5, 113.7; LRMS m/z calcd 
for C14H12N3 0 4 S [M+Ht: 318.1; found 318.8. 
0 /~'CC~Xo N II I H O 
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Preparation of Compound 32. 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 4-isopropylaniline (0.31 g, 
2.30 mmol), and DMF (6 mL) were used to afford compound 
25 
30 
35 
32 (0.24 g, 59%) as a pink solid: 1H NMR (400 MHz, 40 
(CD3 ) 2 SO) ll 12.15 (s, lH), 12.08 (s, lH), 10.21 (br s, lH), 
7.52 (d, J=2.0 Hz, lH), 7.44 (dd, J=8.4, 2.0 Hz, lH), 7.18 (d, 
J=8.4 Hz, lH), 7.09 (app dt, J=8.4, 2.0 Hz, 2H), 6.99 (app 
dt, J=8.4, 2.0 Hz, 2H), 2.76 (hep., J=6.8 Hz, lH), 1.10 (d, 
J=6.8 Hz, 6H); 13C NMR (100 MHz, (CD3 ) 2 SO) Ii 155.2, 45 
155.0, 144.1, 135.2, 133.8, 129.3, 127.0, 125.8, 121.5, 
120.3, 115.5, 113.75, 113.69, 32.7, 23.8; LRMS m/z calcd 
for C17H18N3 0 4 S [M+Ht: 360.1; found 360.8. 
50 Q o II H /S'CCNXO N II I I a 
# N O 
55 
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Preparation of Compound 33. 
As described for the synthesis of compound 29, com- 60 
pound A (0.30 g, 1.15 mmol), N-methylaniline (0.25 mL, 
2.30 mmol), and DMF (6 mL) were used to afford compound 
54 
125.9, 122.3, 120.0, 115.4, 114.5, 114.4, 38.0; LRMS m/z 
calcd for C15H14N30 4 S [M+Ht: 332.1; found 332.8. Clu O I II H 
~ /S'CCNXO N II I I a 
# N O 
H 
Preparation of Compound 34. 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 4-chloro-N-methylaniline 
(0.28 mL, 2.30 mmol), and DMF (6 mL) were used to afford 
compound 34 (0.16 g, 38%) as a white solid: 1H NMR (400 
MHz, (CD3 ) 2 SO) Ii 12.26 (s, lH), 12.00 (s, lH), 7.42 (d, 
J=8.8 Hz, 2H), 7.24 (d, J=8.8 Hz, 2H), 7.23 (s, lH), 7.12 (m, 
2H), 3.09 (s, 3H); 13C NMR (100 MHz, (CD3 ) 2 SO) ll 155.2, 
154.8, 140.0, 131.7, 129.8, 129.3, 128.9, 128.6, 128.1, 
125.9, 122.4, 115.5, 114.5, 37.8; LRMS m/z calcd for 
C15H13ClN3 0 4 S [M+Ht: 366.0; found 366.8. 
0 /~'CC~Xo N II I I a 
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Preparation of Compound 35. 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 4-isopropyl-N-methylaniline 
(0.34 g, 2.30 mmol), and DMF (6 mL) were used to afford 
compound 35 (0.20 g, 48%) as a white solid: 1H NMR (400 
MHz, (CD3 ) 2 SO) Ii 12.25 (s, lH), 12.00 (s, lH), 7.34 (s, 
lH), 7.23 (m, lH), 7.21 (dt, J=8.8, 2.4 Hz, 2H), 7.00 (dt, 
J=8.8, 2.4 Hz, 2H), 3.09 (s, 3H), 2.88 (hep., J=7.2 Hz, lH), 
1.18 (d, J=7.2 Hz, 6H); 13C NMR (100 MHz, (CD3 ) 2 SO) Ii 
155.2, 154.8, 147.5, 138.8, 130.2, 129.5, 126.8, 126.4, 
125.9, 122.3, 115.5, 114.5, 114.4, 38.2, 33.0, 23.8; LRMS 
mlz calcd for C18H20N3 0 4 S [M+Ht: 374.1; found 374.8. 
0 
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Preparation of Compound 36. 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 2-methoxy-N-methylaniline 
(0.31 mL, 2.30 mmol), and DMF (6 mL) were used to afford 
compound 36 (0.12 g, 29%) as a white solid: 1H NMR (400 
MHz, (CD3 ) 2 SO) Ii 12.23 (s, lH), 11.99 (s, lH), 7.40 (d, 
33 (0.27 g, 71%) as a white solid: 1H NMR (400 MHz, 
(CD3 ) 2 SO) ll 12.24 (s, lH), 12.00 (s, lH), 7.34 (d, J=8.0 Hz, 
2H), 7.31-7.29 (m, 2H), 7.22 (s, lH), 7.20 (d, J=l.6 Hz, lH), 
7.10 (m, 2H), 3.12 (s, 3H); 13C NMR (100 MHz, (CD3 ) 2 SO) 
Ii 155.2, 154.8, 141.1, 129.8, 129.6, 129.0, 127.4, 126.4, 
65 1=2.0 Hz, lH), 7.38-7.34 (m, lH), 7.33-7.30 (m, lH), 7.24 
(d, J=8.4 Hz, lH), 7.14 (dd, J=8.0, 1.2 Hz, lH), 7.01 (dd, 
J=8.0, 1.2 Hz, lH), 6.93 (td, J=7.6, 1.2 Hz, lH), 3.36 (s, 3H), 
US 10,208,000 B2 
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3.08 (s, 3H); 13C NMR (100 MHz, (CD3 ) 2 SO) Ii 156.2, 
155.3, 154.9, 132.9, 131.0, 129.8, 129.2, 128.6, 125.7, 
122.2, 120.4, 115.2, 114.2, 112.6, 55.2, 37.7; LRMS m/z 
calcd for C16H16BrN3 0 5 S [M+Ht: 362.1; found 362.8. 
56 
MHz, (CD3 ) 2 SO) Ii 12.23 (s, lH), 11.99 (s, lH), 7.33 (d, 
l=l.6 Hz, lH), 7.27-7.22 (m, 3H), 6.88 (m, lH), 6.67-6.65 
(m, 2H), 3.70 (s, 3H), 3.11 (s, 3H); 13C NMR (100 MHz, 
(CD3 ) 2 SO) Ii 159.3, 155.1, 154.8, 142.2, 130.0, 129.60, 
5 129.57, 125.8, 122.3, 118.2, 115.4, 114.4, 112.8, 112.3, 55.2, 
38.0; LRMS m/z calcd for C16H16N30 5 S [M+Ht: 362.1; 
found 362.8. 
10 
Preparation of Compound 37. 15 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 3-fluoro-N-methylaniline 
(0.26 mL, 2.30 mmol), and DMF (6 mL) were used to afford 
compound 37 (0.06 g, 15%) as a white solid: 1H NMR (400 
20 MHz, (CD3 ) 2 SO) Ii 12.26 (s, lH), 12.00 (s, lH), 7.39 (app 
q, 1=8.0 Hz, lH), 7.30 (s, lH), 7.23 (m, 2H), 7.16 (td, 1=8.8, 
5.6 Hz, lH), 7.03 (dt, 1=10.8, 2.4 Hz, lH), 6.99 (m, lH), 
3.12 (s, 3H); 13C NMR (100 MHz, (CD3 ) 2 SO) Ii 163.0, 
160.6, 155.2, 154.8, 142.8, 142.7, 130.5, 130.4, 129.8, 25 
129.4, 125.9, 122.3, 122.09, 122.06, 115.5, 114.4, 114.2, 
114.0, 113.4, 113.1, 37.7; LRMS m/z calcd for 
C15H13FN3 0 4 S [M+Ht: 350.1; found 350.8. 
OMe 
D o II H MeO 1/Ml(YNXO 
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Preparation of Compound 40. 
As described for the synthesis of compound 29, com-
pound A (0.20 g, 0.77 mmol), 3,5-dimethoxy-N-methylani-
line (0.26 g, 1.54 mmol), and DMF (4 mL) were used to 
afford compound 40 (0.03 g, 10%) as a white solid: 1 H NMR 
(400 MHz, (CD3 ) 2 SO) 012.23 (s, lH), 12.00 (s, lH), 7.37 (d, 
1=2.0 Hz, lH), 7.29 (dd, 1=8.0, 2.0 Hz, lH), 7.23 (d, 1=8.0 
Hz, lH), 6.45 (t, 1=2.0 Hz, lH), 6.25 (d, 1=2.0 Hz, 2H), 3.67 
(s, 3H), 3.65 (s, 3H), 3.09 (s, 3H); 13C NMR (100 MHz, 
&Br O 
30 (CD3 ) 2 SO) Ii 160.2, 155.2, 154.8, 142.8, 130.1, 129.6, 
125.8, 122.3, 115.4, 114.4, 104.6, 99.1, 55.3, 38.0; LRMS 
m/z calcd for C17H18N3 0 6S [M+Ht: 392.1; found 392.8. /~u~xo N II I I a 
# N O 
35 
H 
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Preparation of Compound 38. 
As described for the synthesis of compound 29, com-
pound A (0.30 g, 1.15 mmol), 3-bromo-N-methylaniline 
(0.29 mL, 2.30 mmol), and DMF (6 mL) were used to afford 
compound 38 (0.02 g, 4%) as a white solid: 1H NMR (400 45 
MHz, (CD3 ) 2 SO) ll 12.27 (s, lH), 12.01 (s, lH), 7.51 (ddd, 
1=7.6, 2.0, 1.2 Hz, lH), 7.35 (t, 1=2.0 Hz, lH), 7.32 (d, 1=8.0 
Hz, lH), 7.29 (m, lH), 7.23 (m, 2H), 7.14 (ddd, 1=7.6, 2.0, 
1.2 Hz, lH), 3.11 (s, 3H); 13C NMR (100 MHz, (CD3 ) 2 SO) 
Ii 155.2, 154.8, 142.6, 130.8, 129.8, 129.3, 129.1, 129.0, 50 
125.9, 125.1, 122.3, 121.3, 115.5, 114.5, 37.7; LRMS m/z 
calcd for C15H13BrN3 0 4 S [M+Ht: 410.0; found 410.8. 
55 
60 
Preparation of Compound 39. 
As described for the synthesis of compound 29, com-
pound A (0.20 g, 0.77 mmol), 3-methoxy-N-methylaniline 65 
(0.20 mL, 1.54 mmol), and DMF ( 4 mL) were used to afford 
compound 39 (0.05 g, 17%) as a gray solid: 1 H NMR ( 400 
0 
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Preparation of Compound 41. 
As described for the synthesis of compound 29, com-
pound A (0.20 g, 0.77 mmol), 3-methyl-N-methylaniline 
(0.19 mL, 1.54 mmol), and DMF (4 mL) were used to afford 
compound 41 (0.15 g, 58%) as a white solid: 1H NMR (400 
MHz, (CD3 ) 2 SO) Ii 12.23 (s, lH), 11.98 (s, lH), 7.32 (m, 
lH), 7.24-7.20 (m, 3H), 7.11 (m, lH), 6.96 (m, lH), 6.85 (m, 
lH), 3.09 (s, 3H), 2.27 (s, 3H); 13C NMR (100 MHz, 
(CD3 ) 2 SO) Ii 155.2, 154.8, 141.1, 138.3, 130.0, 129.5, 
128.7, 128.0, 127.1, 125.8, 123.2, 122.3, 115.4, 114.4, 38.0, 
20.8; LRMS m/z calcd for C16H16N30 4 S [M+Ht: 346.1; 
found 346.8. 
0 /~u~xo N II I I a 
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Preparation of Compound 42. 
As described for the synthesis of compound 29, com-
poundA (0.20 g, 0.77 mmol), 3-ethyl-N-methylaniline (0.21 
US 10,208,000 B2 
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g, 1.54 mmol), and DMF (4 mL) were used to afford 
compound 42 (0.20 g, 74%) as a white solid: 1H NMR (400 
MHz, (CD3)2SO) ll 12.23 (s, lH), 11.98 (s, lH), 7.30 (s, lH), 
7.25 (t, 1=8.8, lH), 7.23 (s, lH), 7.14 (d, 1=7.2 Hz, lH), 6.89 
(m, 2H), 3.10 (s, 3H), 2.55 (q, 1=8.0 Hz, 2H), 1.09 (t, 1=8.0 5 
Hz, 3H); 13C NMR (100 MHz, (CD3)2SO) Ii 155.1, 154.8, 
144.6, 141.1, 129.9, 129.5, 128.8, 126.9, 125.8, 123.7, 
122.3, 115.4. 114.5, 38.1, 27.9, 15.4; LRMS m/z calcd for 
C17H18N30 4 S [M+Ht: 360.1; found 360.8. 
Preparation of Compound 45. 
As described for the synthesis of compound 29, com-
pound A (0.03 g, 0.13 mmol), 3-t-butyl-N-methylaniline 
(0.04 g, 0.27 mmol), and DMF (1 mL) were used to afford 
compound 45 (0.03 g, 58%) as a brown solid: 1 H NMR ( 400 
MHz, (CD3)2SO) Ii 12.25 (s, lH), 11.99 (s, lH), 7.32 (dt, 
1=8.0, 1.6 Hz, lH), 7.30-7.26 (m, 2H), 7.23 (m, 2H), 6.94 (t, 
l=l.6 Hz, lH), 6.92 (d, l=l.6 Hz, lH), 3.11 (s, 3H), 1.17 (s, 
9H); 13C NMR (100 MHz, (CD3)2SO) ll 155.1, 154.7, 151.5, 
0 
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Preparation of Compound 43. 
10 140.9, 129.9, 129.5, 128.6, 125.7, 124.3, 124.0, 123.3, 
122.3, 115.4, 114.6, 38.2, 34.3, 30.8; LRMS m/z calcd for 
C19H21N30 4 S [M+Ht: 387.1; found 387.8. 
Preparation of Compound 46. 
As described for the synthesis of compound 29, com-
15 pound A (0.20 g, 0.77 mmol), N-methyl-2-naphthylamine 
(0.24 g, 1.54 mmol), and DMF (4 mL) were used to afford 
compound 46 (0.16 g, 55%) as an orange solid: 1H NMR 
(400 MHz, (CD3)2SO) Ii 12.24 (s, lH), 11.95 (s, lH), 
7.95-7.86 (m, 3H), 7.64 (d, 1=2.0 Hz, lH), 7.52 (m, 2H), 
20 7.31-7.29 (m, 2H), 7.23 (m, 2H), 3.22 (s, 3H); 13C NMR 
(100 MHz, (CD3)2SO) Ii 155.1, 154.8, 138.6, 132.9, 131.7, 
129.8, 129.6, 128.5, 127.9, 127.5, 126.6, 126.4, 125.9, 
124.9, 124.3, 122.4, 115.5, 114.4, 38.1; LRMS m/z calcd for 
As described for the synthesis of compound 29, com-
pound A (0.07 g, 0.27 mmol), 3-i-propyl-N-methylaniline 
(0.08 g, 0.54 mmol), and DMF (1.5 mL) were used to afford 
compound 43 (0.06 g, 60%) as a white solid: 1H NMR (400 
MHz, (CD3)2SO) Ii 12.25 (s, lH), 11.99 (s, lH), 7.27 (d, 25 
1=8.0 Hz, lH), 7.26 (t, 1=8.0 Hz, lH), 7.22 (d, 1=2.0 Hz, 
lH), 7.21 (dd, 1=8.4, 1.6 Hz, lH), 7.17 (dt, 1=8.0, 1.2 Hz, 
lH), 6.92 (ddd, 1=8.0, 2.0, 1.2 Hz, lH), 6.85 (t, 1=2.0 Hz, 
lH), 3.10 (s, 3H), 2.81 (hep., 1=6.8 Hz, lH), 1.10 (d, 1=6.8 
Hz, 6H); 13C NMR (100 MHz, (CD3)2SO) Ii 155.2, 154.8, 30 
149.3, 141.1, 129.9, 129.5, 128.8, 125.8, 125.5, 124.3, 
124.2, 122.3, 115.4, 114.6, 38.1, 33.1, 23.6; LRMS m/z 
calcd for C18H19N30 4 S [M+Ht: 373.1; found 373.8. 
C19H15N30 4 S [M+Ht: 381.1; found 381.8. 
OMe 
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Preparation of Compound 44. 
As described for the synthesis of compound 29, com-
poundA (0.06 g, 0.25 mmol), 3-butyl-N-methylaniline (0.08 
g, 0.49 mmol), and DMF (1.5 mL) were used to afford 
compound 44 (0.10 g, 100%) as a pink solid: 1H NMR (400 
MHz, (CD3)2SO) Ii 12.26 (s, lH), 11.98 (s, lH), 7.27 (m, 
lH), 7.25 (s, lH), 7.22 (m, 2H), 7.11 (d, 1=8.0 Hz, lH), 6.94 
(m, lH), 6.80 (t, 1=2.0 Hz, lH), 3.11 (s, 3H), 1.42-1.37 (m, 
3H), 1.24-1.17 (m, 3H), 0.82 (t, 1=7 .6 Hz, 3H); 13C NMR 
(100 MHz, (CD3)2SO) Ii 155.2, 154.8, 143.2, 141.0, 129.9, 
129.5, 128.7, 127.4, 125.9, 125.8, 124.1, 122.3, 115.4, 
114.6, 38.1, 34.5, 33.0, 21.6, 13.8; LRMS m/z calcd for 
C18H19N30 4 S [M+Ht: 373.1; found 373.8. 
35 
#' N O 
H 
Preparation of Compound 47. 
As described for the synthesis of compound 29, com-
poundA (0.09 g, 0.35 mmol), N-methyl-4-methoxy-2-naph-
40 thylamine (0.13 g, 0.70 mmol), and DMF (2 mL) were used 
to afford compound 47 (0.03 g, 21 % ) as a yellow solid: 1 H 
NMR (400 MHz, (CD3)2SO) ll 12.24 (s, lH), 11.97 (s, lH), 
8.11-8.09 (m, lH), 7.82-7.80 (m, lH), 7.55-7.48 (m, 2H), 
7.35 (d, 1=2.0 Hz, lH), 7.31 (dd, 1=8.4, 2.0 Hz, lH), 7.23 (d, 
45 1=8.4 Hz, lH), 7.20 (d, l=l.2 Hz, lH), 6.71 (d, 1=2.0 Hz, 
lH), 3.87 (s, 3H), 3.21 (s, 3H); 13C NMR (100 MHz, 
(CD3)2SO) Ii 155.2, 154.9, 154.8, 139.1, 133.4, 129.9, 
129.7, 127.8, 127.2, 125.9, 125.8, 123.7, 122.5, 121.3, 
116.7, 115.4, 114.5, 103.9, 55.7, 38.2; LRMS m/z calcd for 
50 C20H17N30 5S [M+Ht: 411.1; found 411.8. 
2. Biochemistry and Biology: 
2.1. Protein, Reagents, and Small-Molecule Libraries. 
Recombinant Mtb Eis protein (Eis_Mtb ), AAC( 6')-Ie/ 
APH(2")-Ia, AAC(3)-IV, and AAC(2')-Ic were expressed 
55 and purified as reported previously. All chemicals including 
5',5-dithiobis-(2-nitrobenzoic acid) (DTNB), Tween® 80, 
neomycin B (NEO), kanamycin A (KAN), acetyl-CoA (Ac-
CoA), and chlorhexidine were purchased from Sigma-Al-
drich (St. Louis, Mo., USA). Albumin-dextrose-catalase 
60 (ADC) was from BD Biosciences (San Jose, Calif., USA). 
The high-throughput screening (HTS) to identify inhibitors 
of the acetyltransferase activity of purified Eis_Mtb was 
carried out at the Center for Chemical Genomics (CCG, 
University of Michigan) against 123,000 compounds from 
65 (i) a ChemDiv library (120,000), (ii) the BioFocus NCC 
library, and (iii) the MicroSource MS2000 library. All small 
molecules were dissolved in DMSO prior to testing. The 
US 10,208,000 B2 
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immediate follow-up assays to confirm inhibition or triage 
false positives were performed with hit compounds from 
fresh powders purchased from ChemDiv (San Diego, Calif., 
USA). Note: All concentrations noted below are the final 
concentrations in the assays. 
2.2. Eis Chemical Library Screening. 
HTS was performed as previously described.4 Briefly, 
absorbance signal from the reaction of the enzymatically 
released CoASH with Ellman's reagent, DTNB, at 412 nm 
(E412=14150 M- 1 cm- 1 ) was used to monitor the acetylation 
by Eis_Mtb. The reactions (40 µL) contained Tris (50 mM, 
pH 8.0 adjusted at room temperature), Eis (0.25 µM), NEO 
(100 µM), AcCoA (40 µM), DTNB (0.5 mM), and library 
compounds (20 µM). Chlorhexidine (5 µM) and DMSO 
(0.5%) served as positive and negative controls, respec-
tively. Plates were incubated at room temperature and read 
on a PHERAstar plate reader at 5 min after initiation of the 
reaction. The average Z' score for the HTS assay was 0.60. 
2.3. Hit Validation. 
Hit compounds were defined as displaying 3-fold or 
stronger inhibition than the standard deviation ( calculated 
for the inert compounds) in the HTS. These compounds 
were tested in triplicate. The compounds that exhibited 
reproducible inhibitory activity in two out of three trials 
were then tested in dose-response assays in the concentra-
tion range from 20 µM to 78 nM (generated by 2-fold 
dilutions of the compound stock), and IC50 values were 
obtained for all compounds displaying dose-dependent inhi-
bition. 
2.4. Inhibition Kinetics. 
Absorbance was measured on a SpectraMax MS plate 
reader, for the reaction mixtures in 96-well plates (Thermo 
Fisher Scientific). Measurements were taken every 30 s for 
60 
in 50 mL polypropylene tubes containing glass beads and 
vortexed for 30 sec. The cultures were kept still for 10 min, 
and then 90 µL aliquots were distributed into the wells of a 
clear 96-well culture plate. Compounds were initially tested 
5 at concentrations that were either 100-fold higher than their 
IC50 KAN or at 100 µM if the IC50,KAN value was unknown 
or c~uld not be achieved while keeping the DMSO concen-
trations 1 % in test wells. Working stocks for each compound 
were prepared at concentrations twice that of the desired 
1 o final concentration in fresh 7H9 medium, and 100 µL of each 
of these working stocks was added to the 90 µL of bacterial 
cultures in the wells. The plates were incubated at 37° C. for 
24 h in a humid environment before the addition of KAN (10 
µL). Growth ofH37Rv was evaluated at 2.5, and 1.25 µg/mL 
15 KAN while growth ofK204 was evaluated at 10, 5, 2.5, and 
1.25 µg/mL KAN. The plates were incubated at 37° C. for 
6 days after the addition of KAN. Then, 40 µL of alamar blue 
diluted 1:2 in 10% Tween® 80 was added to each well and 
the plates continued to be incubated 3 7° C. The color of each 
20 well was preliminarily evaluated 24 h after the addition of 
alamar blue, with a final evaluation after 48 h. Alamar blue 
changes from indigo blue to pink as a result of bacterial 
growth. The lowest concentration of KAN that resulted in no 
change in color was defined as the MIC for each concen-
25 tration of an inhibitory compound. Compound screening 
was carried out on biological replicates in duplicate. Several 
controls were included with every compound: uninoculated 
7H9, compound and inoculated 7H9 only, inoculated 7H9+ 
DMSO only, and inoculated 7H9 only. For each plate, 2004 
30 of sterile water was added to all perimeter wells to minimize 
evaporation. 
3. Structural Biology: 
3.1. Purification of EisC204A. 
10 min. Compounds were first serially dissolved in Tris-HCl 
(50 mM, pH 8.0, containing 10% v/v DMSO). A mixture (50 35 
µL) of Eis (1 µM), KAN (400 µM), and Tris-HCl (50 mM, 
pH 8.0) was added to the inhibitors and incubated for 10 
min. Reactions were initiated by the addition of a mixture 
(50 µL) ofDTNB (8 mM), AcCoA (2 mM), and Tris-HCl (50 
mM, pH 8.0). All assays were performed in triplicate. IC50 40 
values were calculated by curved fitting to a Hill plot with 
KaleidaGraph 3.6 software (Table 2 and FIG. 1). 
The active point mutant EisC204A that is less prone to 
oxidation than the wild-type Eis_Mtb was overexpressed in 
BL21(DE3) E.coli and purified as previously reported, with 
only minor modifications, as follows. The EisC204A-
pET28a plasmid was transformed into E. coli BL21 (DE3) 
chemically competent cells and plated onto LB agar con-
taining kanamycin (KAN; 50 µg/mL). After overnight incu-
bation, a single colony from the plate was inoculated into LB 
broth (5 mL) containing KAN (50 µg/mL) (LB/KAN). This 
culture was grown at 37° C. until the attenuance at 600 nm 
of 0.5, then the culture was inoculated into 4 L of LB/KAN 
and grown at 37° C.At the attenuance at 600 nm of-0.1, the 
culture was transferred to 16° C. for 1.5 h, and then IPTG 
2.5. Inhibitor Selectivity. 
To investigate the selectivity of our inhibitors towards Eis, 
compounds 39 and 46 were tested against three additional 45 
AAC enzymes: AAC(2')-Ic, AAC(3)-IV, and AAC(6')-Ie/ 
APH(2")-Ia. The conditions utilized for determination of 
IC50 values were also used here under the optimum condi-
tions for each enzyme. Compounds 39 and 46 (200 to 100 
pM) were dissolved in buffer (50 mM MES pH 6.6 for 50 
AAC(6')-Ie/APH(2")-Ia and AAC(3)-IV and 100 mM 
sodium phosphate pH 7.4 for AAC(2')-Ic). Enzyme (0.25 
µM for AAC(6')-Ie/APH(2")-Ia, 0.125 µM for AAC(3)-IV 
and AAC(2')-Ic), NEO (100 µM), and AcCoA (150 µM) 
were used for these assays. AAC(3)-IV and AAC(2')-Ic 55 
experiments were incubated at 25° C. AAC(6')-Ie/APH(2")-
Ia experiments were incubated at 37° C. All other methods 
and concentrations are the same as for the experiments with 
Eis_Mtb. 
2.6. Mycobacterial MIC Determination by Alamar Blue 60 
Assay. 
was added at the final concentration of0.5 mM. The induced 
culture was grown for an additional 16-18 hat 16° C. with 
shaking (200 rpm). All following purification steps were 
done at 4 ° C. The cells were pelleted by centrifugation at 
5,000 rpm for 10 min. The cell pellets were resuspended in 
chilled lysis buffer (NaCl (300 mM), Tris-HCl pH 8.0 
adjusted at room temperature ( 40 mM), glycerol (10% v/v), 
and ~-mercaptoethanol (2 mM)). The cells were then dis-
rupted by sonication and the insoluble material was removed 
by centrifugation at 35,000xg for 45 min at 4° C. The 
supernatant was passed through a 0.45 µm Millex-HV PVDF 
filter (Millipore, Billerica, Mass., USA) and then loaded 
onto a 5 mL Ni-IMAC HisTrap FF column (GE Healthcare) 
pre-equilibrated in the lysis buffer. The column was washed 
with 100 mL oflysis buffer containing 20 mM imidazole and 
then the protein was eluted in 10 mL of lysis buffer con-
taining 200 mM imidazole. The eluate was concentrated 
using anAmicon Ultra-15 (10,000 MWCO) centrifugal filter 
Mtb strains H37Rv and K204 were inoculated from 
frozen stocks into Middlebrook 7H9 broth supplemented 
with ADC (10%), Tween® 80 (0.05%), and glycerol (0.4%), 
and incubated at 37° C. until turbidity appeared. The cul-
tures were diluted with fresh 7H9 medium to the attenuance 
at 600 nm of 0.2, further diluted 1 :25 in fresh 7H9 medium 
65 device (Millipore) to the volume of 5 mL. The protein was 
then purified on a size-exclusion S-200 column (GE Health-
care) equilibrated in gel filtration buffer (Tris-HCl pH 8.0 
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Genomics (CCG, University of Michigan) against 123,000 
compounds from (i) a ChemDiv library (120,000), (ii) the 
BioFocus NCC library, and (iii) the MicroSource MS2000 
library. All small molecule stock solutions for HTS were 
( 40 mM), NaCl (100 mM), and ~-mercaptoethanol (2 mM)). 
The Eis-containing fractions were pooled and concentrated 
using an Amicon Ultra (10,000 MWCO) centrifugal filter 
device (Millipore) to 4 mg/mL. The pure Eis protein was 
stored on ice at 4 ° C. 
3.2. Crystallization, Diffraction Data Collection, and 
Structure Determination and Refinement of EisC204A-
CoA-Inhibitor 39 Complex. 
5 prepared in DMSO. The activity of promising compounds 
was confirmed using fresh powder samples purchased from 
ChemDiv (San Diego, Calif., USA). Note: All concentra-
tions noted below are final concentration. 
Crystals were grown by vapor diffusion in hanging drops 
containing 14 of concentrated (4 mg/mL) EisC204A protein 10 
containing KAN (10 mM), and CoA (8 mM) mixed with 1 
Eis Chemical Library Screening. 
Screening of small-molecule libraries was performed as 
previously described. (3) Briefly, a UV-Vis assay monitoring 
the reaction of the enzymatically released CoASH with 
Ellman's reagent, DTNB, at 412 nm (E412=14150 M- 1 cm- 1 ) 
was used to determine inhibition of Eis. The final reactions 
15 (40 µL) contained Tris (50 mM, pH 8.0 adjusted at room 
temperature), Eis (0.25 µM), NEO (100 µM), AcCoA (40 
µM), DTNB (0.5 mM), and molecules from the HTS librar-
ies (20 µM). Chlorhexidine (5 µM) and DMSO (0.5%) were 
used as positive and negative controls, respectively. Plates 
µL of the reservoir solution (Tris-HCI pH 8.5 adjusted at 
room temperature (100 mM), PEG 8,000 (10-15% w/v), and 
(NH4 ) 2S04 (0.4 M)). The drops were equilibrated against 1 
mL of the reservoir solution at 22° C. Single crystals were 
obtained in 2-3 weeks. The crystals were first gradually 
transferred into the reservoir solution. The (NH4 ) 2S04 and 
KAN were then exchanged out of the solvent by a gradual 
transfer into the reservoir solution lacking (NH4 ) 2 S04 : 
(Tris-HCI pH 8.5 (100 mM) and PEG 8,000 (13% w/v)). 
Then the crystals were gradually transferred into the cryo-
protectant solution (Tris-HCI pH 8.5 (100 mM), PEG 8,000 
(13% w/v), and glycerol (20% v/v)) and incubated in this 
solution for 10 min. Upon the incubation, the crystals were 
transferred in the inhibitor solution (the cryoprotectant solu- 25 
tion containing 0.5 mM inhibitor) for 30 min, and then 
frozen in liquid nitrogen by quick immersion. 
20 were incubated at room temperature and read on a 
PHERAstar plate reader at a single end point reading at 5 
min after initiation of the reaction. The average Z' score for 
the entire high-throughput screening assay was 0.60. 
The X-ray diffraction data were collected at 100 K at 
synchrotron beamline 22-ID of the Advanced Photon Source 
at the Argonne National Laboratory (Argonne, Ill.). The data 30 
were processed with HKL2000. The crystal form was the 
same as that of wild-type Eis-CoA-acetamide complex 
determined previously by our group (PDB code 3R1K) and 
contained one Eis monomer in the asymmetric unit, with the 
Eis hexamer generated by crystal symmetry operations. This 35 
crystal structure (without ligands or water molecules) was 
used as the starting point, and rigid body refinement was 
performed by Refmac, with the Eis monomer as a single 
rigid-body domain. After the rigid body refinement, strong 
difference F O -F c electron density for the inhibitor 39 mo!- 40 
ecule and a part of CoA was apparent, which allowed 
building of the molecules into the difference electron density 
with Coot program. The structures of EisC204A-CoA-in-
hibitor 39 complex was iteratively built and refined using 
programs Coot and Refmac, respectively. The data collec- 45 
tion and refinement statistics for the structures reported here 
are given in Table 3. The EisC204A-CoA-inhibitor complex 
structures have been deposited in the Protein Data Bank. The 
accession number is 5EBV for the crystal structure of 
acetyltransferase Eis from Mycobacterium tuberculosis in 50 
complex with inhibitor l lc and CoA; and the accession 
number is 5EC4 for the crystal structure of acetyltransferase 
Eis from Mycobacterium tuberculosis in complex with 
inhibitor 13g and CoA. 
Hit Validation. 
Compound from the initial screen determined to be hits 
(>3a, statistically above the negative control) were tested in 
triplicate. All compounds inhibiting Eis in two out of three 
trials were then tested in a dose-dependent manner using 
two-fold dilutions from 20 µM to 78 nM, and IC50 values 
were determined for all compounds having dose-dependent 
activity. 
Inhibition Kinetics. 
All IC50 values were determined by UV-Vis assays moni-
toring CoASH release (see Eis chemical library screening 
above) by using a Multimode SpectraMax MS plate reader 
in 96-well plates. Reactions (200 µL) contained inhibitors 
(200 µM to 2 pM), Tris (50 mM, pH 8.0 adjusted at room 
temperature), Eis (0.25 µM), AcCoA (500 µM), KAN (100 
µM), and DTNB (2 mM). To calculate IC50 values, a Hill 
plot fit was generated with KaleidaGraph 4.1 software by 
using the initial rates (first 2-5 min ofreactions) normalized 
to reactions where inhibitors were omitted. IC50 values are 
presented in Table 7 and representative dose-response 
curves are displayed in FIG. 5. 
Inhibitor Selectivity. 
Compounds 46b and 46c were tested against three addi-
tional AAC enzymes: AAC(6')/APH(2"), AAC(3)-IV, and 
AAC(2')-Ic. The conditions described above for determina-
tion of IC50 values were used under the optimum conditions 
for each enzyme. Compounds 46b and 46c (200 µM to 100 
pM) were dissolved in buffer (50 mM MES pH 6.6 for 
AAC(6')/APH(2") and AAC(3)-IV and 75 mM sodium 
phosphate pH 7.4 for AAC(2')-Ic). Enzyme (0.25 µM for 
AAC(6')/APH(2"), 125 nM for AAC(3)-IV andAAC(2')-Ic), 
Example 2 
Protein, Reagents, and Small-Molecule Libraries. 
55 NEO (100 µM), and AcCoA (150 µM) were used for these 
tests. AAC(6')/APH(2") experiments were incubated at 37° 
C. while AAC(3)-IV and AAC(2')-Ic experiments were 
incubated at 25° C. All other methods and concentrations 
The Eis from Mtb, (1) AAC(6')/APH(2"), (2) AAC(3)-IV, remained identical to those for the experiments with Eis. 
Mycobacterial MIC Determination by Alamar Blue 
Assay. 
(2) and AAC(2')-Ic(l) were overexpressed and purified as 60 
previously reported in the literature. All reagents including 
5',5-dithiobis-(2-nitrobenzoic acid) (DTNB), Tween® 80, 
neomycin B (NEO), kanamycin A (KAN), acetyl-CoA (Ac-
CoA), and chlorhexidine were purchased from Sigma-Al-
drich (St. Louis, Mo., USA). Albumin-dextrose-catalase 
(ADC) was purchased from BD Biosciences (San Jose, 
Calif., USA). Eis was screened at the Center for Chemical 
Mtb strains H37Rv and K204 were inoculated from 
frozen stocks into Middlebrook 7H9 broth supplemented 
with ADC (10%), Tween® 80 (0.05%), and glycerol (0.4%), 
65 and incubated at 37° C. until turbid. Cultures were diluted to 
an A600 of 0.2 in fresh 7H9 medium, then additionally 
diluted 1 :25 in 7H9 medium in 50 mL polypropylene tubes 
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containing glass beads, vortexed for 30 sec, allowed to settle 
for 10 min, and 90 µL was distributed into wells of a clear 
96-well culture plate. Compounds were tested at either lOOx 
their IC50 (if known) or 20 µM. Working stocks for each 
compound were prepared at 2x their desired final test 5 
concentration in fresh 7H9 medium, and 100 µL of 2x 
working stocks was added to test wells containing 90 µL of 
bacteria. Plates were incubated at 37° C. for 24 h in a humid 
environment before the addition of KAN (10 µL ). Growth of 
H37Rv was evaluated at 5, 2.5, 1.25, 0.625, 0.312 and 0.156 10 
µg/mL KAN while growth of K204 was evaluated at 20, 10, 
5, 2.5, 1.25, 0.625 µg/mL KAN. Plates were incubated at 37° 
C. for 6 days after the addition of KAN. Then, 40 µL of 
alamar blue diluted 1:2 in 10% Tween® 80 was added to 
each well and plates were returned to 37° C. The color of 15 
each well was preliminarily evaluated 24 h after the addition 
of alamar blue, with a final evaluation after 48 h. Alamar 
blue changes from indigo blue to pink as a result of bacterial 
growth. The lowest concentration of KAN that resulted in no 
color change was recorded as the MIC for each concentra- 20 
tion of compound. Compound screening was done on bio-
logical replicates in triplicate. Several controls were evalu-
ated with every compound including, uninoculated 7H9, 
compound+inoculated 7H9 only, inoculated 7H9+DMSO 
only, and inoculated 7H9 only. For each plate, 200 µL of 25 
sterile ddH20 was added to all perimeter wells to prevent 
evaporation. 
Purification of EisC204A. 
EisC204A was expressed and purified as described, (4) 
with minor modifications, as follows. The EisC204A- 30 
pET28a construct was transformed into E. coli BL21 (DE3) 
chemically competent cells, plated onto LB agar containing 
kanamycin (KAN; 50 µg/mL). A colony from the transfor-
mation plate was inoculated into LB broth (5 mL) supple-
mented with KAN (50 µg/mL) (LB/KAN) and the culture 35 
was grown at 37° C. until mid-log phase. This 5-mL culture 
was then inoculated into 4 L of LB/KAN and grown at 37° 
C. When attenuance at 600 nmreached-0.1, the culture was 
transferred to 16° C. for -1.5 h, and then IPTG was added 
at the final concentration of 0.5 mM. The induced culture 40 
was grown for an additional 16-18 hat 16° C. (Note: All 
culture growth steps were performed with shaking at 200 
rpm. All purification steps were carried out at 4° C.). The 
cells were harvested by centrifugation at 5,000 rpm for 10 
min at 4 ° C. The cell pellets were resuspended in lysis buffer 
(NaCl (300 mM), Tris-HCl pH 8.0 adjusted at room tern- 45 
perature ( 40 mM), glycerol (10% v/v), and ~-mercaptoetha-
nol (2 mM)). The cells were disrupted by sonication on ice 
and the insoluble cell debris were removed by centrifugation 
at 35,000xg for 45 min at 4 ° C. The supernatant was filtered 
through a 0.45 µm Millex-HV PVDF filter (Millipore, 50 
Billerica, Mass., USA) and applied to a 5 mL Ni-IMAC 
HisTrap FF colunm (GE Healthcare) equilibrated with lysis 
buffer. The protein was then eluted with lysis buffer in a 
64 
stepwise imidazole gradient (6x5 mL fractions of 10 mM 
imidazole, 6x5 mL fractions of 20 mM imidazole, 3x5 mL 
fractions of 50 mM imidazole, and 7x5 mL fractions of 250 
mM imidazole). The eluted fractions containing more than 
95% pure desired protein, as determined by SDS-PAGE, 
were pooled and concentrated using an Amicon Ultra-15 
(5,000 MWCO) centrifugal filter device (Millipore). The 
protein was further purified on a size-exclusion S-200 col-
unm (GE Healthcare) equilibrated in gel filtration buffer 
(Tris-HCl pH 8.0 (40 mM), NaCl (100 mM), and ~-mer-
captoethanol (2 mM)), and the Eis-containing fractions were 
pooled and concentrated using an Amicon Ultra (5,000 
MWCO) centrifugal filter device (Millipore) to 4 mg/mL. 
The pure Eis protein was stored at 4 ° C. 
Crystallization, Diffraction Data Collection, and Structure 
Determination and Refinement of EisC204A-CoA-Inhibitor 
Complexes. 
Crystals were grown by vapor diffusion in hanging drops 
containing 1 µL of concentrated (4 mg/mL) EisC204A 
protein, KAN (10 mM), and CoA (8 mM) mixed with 1 µIL 
of the reservoir solution (Tris-HCl pH 8.5 adjusted at room 
temperature (100 mM), PEG 8,000 (10-15% w/v), and 
(NH4 ) 2 S04 (0.4 M)) equilibrated against 1 mL of the res-
ervoir solution at 22° C. Single crystals were obtained in 2-3 
weeks. The crystals were first gradually transferred into the 
reservoir solution. The (NH4 ) 2S04 and KAN were 
exchanged out of the crystals by a gradual transfer into the 
reservoir solution lacking (NH4 ) 2 S04 (Tris-HCl pH 8.5 (100 
mM) and PEG 8,000 (13% w/v)). CoA remained stably 
bound to Eis during this procedure. Then the crystals were 
gradually transferred into the cryoprotectant solution (Tris-
HCl pH 8.5 (100 mM), PEG 8,000 (13% w/v), and glycerol 
(20% v/v)). After this transfer, the crystals were soaked in 
the inhibitor solution (the cryoprotectant solution containing 
0.5 mM inhibitor) for 30 min, then rapidly frozen in liquid 
nitrogen. 
The diffraction data were collected at synchrotron beam-
line 22-ID of the Advanced Photon Source at the Argonne 
National Laboratory (Argonne, Ill.) at 100 K. The data were 
indexed, integrated and scaled with HKL2000. The crystal 
form coincided with that of wild-type Eis-CoA-acetamide 
complex determined previously by our group (PDB code 
3R1K(l )). The Eis from this structure was the starting point, 
and performed rigid body refinement by Refmac. After rigid 
body refinement, strong difference F O -F c electron density for 
an inhibitor molecule and a part of CoA was apparent, which 
allowed facile building of these molecules by using Coot. 
The structures of EisC204A-CoA-inhibitor complexes were 
iteratively built and refined using programs Coot and Ref-
mac, respectively. The data collection and refinement sta-
tistics for the structures reported here are given in Table 8. 
The EisC204A-CoA-inhibitor Ile and 13g structures were 
deposited in the Protein Data Bank with the PDB accession 
numbers 5EBV and 5EC4, respectively. 
TABLE 8 
X-ray diffraction data collection and refinement statistics for the 
EisC204A-CoA-inhibitor llc and EisC204A-CoA-inhibitor 13g ternary 
complex structures. 
Data collection 
Space group 
Number of monomers per asymmetric Wlit 
Unit cell dimensions 
a, b, c (A) 
a, b, g (*) 
Resolution (A) 
Ifs 
llc 
R32 
1 
175.2, 175.2, 122.3 
90, 90, 120 
50.0-2.2 (2.24-2.20)" 
21 (2.9) 
13g 
R32 
1 
175.6, 175.6, 122.2 
90, 90, 120 
50.0-2.2 (2.24-2.20)" 
24 (4.0) 
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TABLE 8-continued 
X-ray diffraction data collection and refinement statistics for the 
EisC204A-CoA-inhibitor 11c and EisC204A-CoA-inhibitor 13g ternary 
complex structures. 
Completeness (%) 99.9 (100) 99.8 (99.4) 
Redundancy 9.5 (9.4) 7.3 (7.3) 
Rmerge 0.11 (0.62) 0.10 (0.56) 
Number of unique reflections 34,661 34,541 
Structure refinement statistics 
Resolution (A) 40.0-2.2 40.0-2.2 
R(%) 19.4 20.0 
Rfree (%) 21.5 23.8 
Bond lengtb deviation (rmsd) from ideal 0.006 0.007 
(A) 
Bond angle deviation (rmsd) from ideal (0 ) 1.34 1.46 
Ramachandran plot statisticsb 
% of residues in most allowed regions 94.1 93.2 
% of residues in additional allowed regions 5.9 6.8 
% of residues in generously allowed regions 0.0 0.0 
% of residues in disallowed regions 0.0 (0 residues) 0.0 (0 residues) 
"Numbers in parentheses indicate the values in the highest-resolution shell. 
bindicates Procheck statistics. (8) 
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What is claimed is: 
1. A compound of the formula: 
wherein R is selected from the group consisting of 
oOO (YF v 
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2. A pharmaceutical composition comprising the com-
pound of claim 1, and a suitable pharmaceutical carrier. 
Rl is selected from: 
20 
25 
30 
3. The composition of claim 2, and further comprising an R2 is selected from: 
aminoglycoside. 35 
4. The composition of claim 3, wherein the aminoglyco-
side is kanamycin (KAN). 
5. A method of inhibiting Eis comprising administering to 
a subject an effective amount of a composition comprising 40 
a compound according to the formula 
50 
wherein R is 
0 "-!)/ 55 
60 
or a compound of claim 1. 
6. A method of inhibiting Eis comprising administering an 65 
effective amount of a composition comprising a compound 
according to the formula: 
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7. d1:he method of claim 6, wherein the compound is 
accor mg to the formula: 
wherein Rl is 
77 
and R2 is -NH(CH2 ) 3 N(CH2 CH3 ) 2 ; Rl is 
~ 
Cl 
and R2 is 
or Rl is 
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8. The method claim 5, wherein a MICKAN value is less 
than about 0.625 µg/mL for Mycobacterium tuberculosis 
(Mtb) strain H37Rv or less than about 5 µg/mL for Mtb 
strain K204. 
9. The method of claim 5, further comprising administer-
ing an aminoglycoside. 
10. The method of claim 9, wherein the aminoglycoside 
is kanamycin (KAN). 
11. A method of treating aminoglycoside-resistant Myco-
bacterium tuberculosis (Mtb ), comprising administering the 
compound of claim 1 to a subject. 
12. The method of claim 11, further comprising admin-
15 istering an aminoglycoside. 
13. The method of claim 12, wherein the aminoglycoside 
is kanamycin (KAN). 
14. The method of claim 12, wherein the aminoglycoside 
20 is administered to a subject in need of treatment for amino-
glycoside-resistant Mtb. 
15. A kit comprising the compound of claim 1, packaged 
together with an aminoglycoside. 
16. The kit of claim 15, wherein the aminoglycoside is 
kanamycin (KAN). 
* * * * * 
